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Abstract
Fracture repair involves complex interactions between cell lineages under the spatiotemporal
control of growth factors and cytokines. Understanding the mechanisms that regulate the commitment and
differentiation of mesenchymal progenitor cells is critical for the advancement of regenerative medicine.
While bone marrow stromal cells (BMSCs) have been well characterized over the years as an
experimental model for osteoblast precursors, increasing evidence suggests a critical role of the
periosteum during fracture. Platelet derived growth factor (PDGF) is a potent mitogen for mesenchymal
cells and an important mediator during fracture healing. The role of PDGF signaling on periosteumderived cells is still unknown. Therefore, the objective of this study is to evaluate the effects of PDGFBB/PDGFR-β signaling on the periosteal derived cells in vitro and fracture healing in vivo.
We detected broad expression of PDGFR-b within the intact periosteum and periosteal callus.
Isolated periosteum-derived progenitor cells were highly responsive to PDGF-BB as demonstrated by
increased proliferation, migration and decreased apoptosis. However, PDGF-BB blocked bone
morphogenetic protein 2 (BMP2)-induced osteogenesis by inhibiting the canonical BMP2/Smad pathway
and downstream target gene expression. This effect is mediated via PDGFR-b and involves ERK1/2
MAPK and PI3K/AKT signaling pathways.
Alpha smooth muscle actin (aSMA) is a marker for mesenchymal stem cells that contribute to
fracture healing. To further understand the role of PDGFR-β signaling in periosteum derived cells in vivo,
we conditionally deleted PDGFR-β using aSMA-CreERT2 crossed with PDGFRβflox/flox mice.
Differentiation assay showed that PDGFR-β deficient cells exhibited significantly enhanced osteogenic
differentiation in vitro. Following femoral fracture, we observed significant decrease of EdU+ periosteal
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cells in aSMA-PDGFRβdel/del mice. Cartilage area/total area decreased after 7 days post fracture. On day
14, we detected a smaller callus with increased mineralized area/total area upon conditionally deleting
PDGFR-β.
Our studies show that PDGF-BB/PDGFR-β signaling as an important regulator for periosteum
derived cells. Therapeutic targeting of the PDGFRb pathway in periosteum-mediated bone repair might
have profound implications in the treatment of bone disease in the future. Further investigations in vivo
will help comprehensively understand the role of PDGF during fracture.
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Chapter 1: Introduction
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Chapter 1
1.0 Overview
The periosteum contains multipotent skeletal progenitor cells which play an essential role during
bone repair(1). Investigating the factors that regulate cellular behavior of the periosteum is important for
further therapeutic application. Platelet-derived growth factor (PDGF) and its receptors are highly
expressed in a variety of cell types during fracture healing(2,3) . Despite extensive studies on bone marrow
stromal cell (BMSC), the effects of PDGF-BB on periosteum derived cells (PDCs) as well as the
signaling pathway utilized by PDGF-BB during bone repair still remains unclear.
In this chapter, we will first review the current understanding of the characteristics of the
periosteum, PDGF and its role in bone regeneration, as well as the crosstalk between different signaling
pathways. We will then present the hypothesis and specific aims, and highlight the significance of the
current study. Finally, we will outline the thesis structure to give an overview of the study.

1.1 Literature Review
1.1.1 Essential role of Periosteum during bone regeneration
Orthopedic Trauma
Fractures are one of the most common injuries and about 16 million bone fractures occur in the
United States each year(4,5). Despite the good healing potential of bone, about 10% still display delayed
healing and complications including non-union, especially with large bone defects. The increasing aging
population further leads to a significant increase in the demand for better fracture treatment. Although
orthopedic procedures have improved significantly over years, novel therapeutic strategies are still
needed, especially when physiological mechanisms of regeneration fail(6). This largely depends on our
understanding of the cellular process and molecular mechanism of tissue repair.
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Fracture Healing
(7)

Fracture repair is a multi-step process involving complex interactions between cell lineages .
(8)

Despite the complexity of this process, it can be divided into four overlapping phases (Figure 1.1) :
(i.)

an initial inflammatory stage with recruitment of progenitor cells

(ii.)

the formation of a soft fibrocartilage callus

(iii.)

the replacement of cartilage by bone (hard callus phase) and

(iv.)

the remodeling into mature lamellar bone.

This characteristic course has been observed in many different animal species (best described in
rodents), and human follow a similar sequence over a longer period of time(1,4).
Immediately after the injury, a hematoma is formed as the result of the rupture of blood vessels.
The hypoxic and low pH environment caused by tissue damage contains inflammatory and antiinflammatory cytokines, as well as immune cells including neutrophils, macrophages and lymphocytes.
Angiogenic factors are released to help remove the debris, deliver nutrients and re-establish normoxic
conditions. Newly formed blood vessels also make a major contribution by providing osteoprogenitor
cells, which are thought to derive from pericytes(9). This inflammatory phase thus initiates the
regenerative healing cascade though the complex interaction between molecular factors and different cell
population, which usually occurs during the first four days in mice.
Under stabilized conditions, most often achieved by compression plates and lag screws, fracture
surfaces are intact and bone heals through direct intramembranous ossification without cartilage
formation(5,10). In other unstabilized cases with considerable interfragmentary movement, periosteal callus
is the major type of bone formation which provides new stability at fracture site.
Figure 1.1. Schematic diagram
of fracture healing phases.
Reprinted from Nat Rev Rheumatol 8,
133-143(4)
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Overlapped with inflammatory phase, soft callus formation starts around day 5 and is driven by
chondrocytes and fibroblasts. Similar to what occurs during endochondral ossification, proliferative
chondrocytes later become hypertrophic and undergo apoptosis. At the same time, mesenchymal
progenitor cells are recruited from nearby periosteal region and differentiate into osteoblasts, resulting in
the formation of new bone. In the final stage, the woven bone is replaced by lamellar bone under the
cooperation of osteoblasts and osteoclasts. Remodeling of periosteal callus restores the original shape as
well as functional competence of bone.
The entire process is well orchestrated under the spatial and temporal control of growth factors
and cytokines. Under the optimal conditions, a fracture heals within a period of time. Non-union fracture
occurs however, in a number of patients, when fibrocartilaginous tissue persists usually >9 months. This
is often associated either with large defect/gap, non-sufficient stabilization, or affected by the patient’s
medical conditions(11,12).

The Periosteum as a central mediator
Bone marrow stromal cells (BMSCs) have been well characterized over the years as an
experimental model for osteoblast precursors and other mesenchymal lineages(13). However, the behavior
and response of the periosteum, which also plays an essential role during fracture healing, is less
investigated(1).
Periosteum is a thin vascularized layer covering the outer surface of bone(14,15). It can be divided
into an outer fibrous layer and an inner cambium layer, which contains progenitor cells and is highly
vascularized. It is well known that the periosteal reaction after fracture is critical for bone
regeneration(1,16,17). The activation of periosteum upon injury was clearly observed as the thickened
osteogenic layer from histology(18). Preservation of the periosteum is required for successful bone
regeneration in patients(19). Children rarely develop fracture nonunion, primarily because of the thickened,
highly osteogenic periosteum(20).
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The importance of periosteum to bone healing has also been demonstrated by a series of bone
graft transplantation experiments. In a segmental femoral bone graft model, Zhang et al(21) transplanted
live isografts from Rosa26A mice into wildtype control mice and traced the fate of periosteal
mesenchymal cells. Histomorphometric analysis demonstrated that ~70% of graft osteogenesis was
attributed to the proliferation and differentiation of periosteal progenitor cells. A similar study compared
the distinct contribution of the periosteum and endosteum/bone marrow to bone healing(22). While
periosteal injuries heal by endochondral ossification, bone marrow injuries heal by intramembranous
ossification(22). Therefore, although bone marrow has been the focus of most studies, it is also critical to
understand the periosteal response during fracture.

Periosteum Derived Cells (PDCs)
The essential role of the periosteum in bone repair has given rise to increased studies on
periosteal derived cells. Human PDCs are considered easily accessible and expandable, causing less
invasiveness to the donor site compared with bone marrow collection(23). Periosteal tissue can be isolated
from the bone of patients by a periosteum elevator, followed by enzymatic digestion or spontaneous cell
egression onto culture dishes(24). For the isolation of mouse PDCs, either a similar method of scraping off
the periosteum or a bone grafting model is usually used(1). Although it is currently difficult to separate the
two layers of the periosteum, several lines of evidences have shown that isolated PDCs are phenotypically
stable and highly comparable between studies(24-26).
Ex vivo expanded PDCs exhibit a fibroblast-like phenotype, which is maintained over several
passages. Under specific differentiation conditions, they can be induced to differentiate into osteogenic,
chondrogenic and adipogenic lineages, confirming the presence of mesenchymal progenitor cells(26-29).
Expanded PDCs also have the potential to form bone and cartilage upon transplantation(26,30), although
whether they have the potential to self-renew(31) is unclear.
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Multiple signaling pathways have been identified to be involved in osteogenic differentiation of
periosteal cells, including Wnt/b-catenin, Transforming Growth Factor-beta (TGF-b)/BMP, as well as
Indian hedgehog (Ihh) and parathyroid hormone related protein (PTHrP)

(32)

. Less is known about the

signal that activates the osteoprogenitor cells of periosteum and stimulates their differentiation into
chondrocytes and osteoblasts.
Previous work from our lab has identified alpha smooth muscle (aSMA) as a marker for
mesenchymal progenitor cells(33). Lineage tracing study demonstrated that the majority of periosteal callus
derived from aSMA+ cells(33,34). While aSMA expressing cells were present on intact periosteum as
indicated by fluorescent reporter, marked expansion of these cells within periosteal callus were noticed 6
days after fracture(34). How those cells are activated upon injury remains an interesting question to answer.
Understanding the activation and regulation of periosteal progenitor cells during fracture healing could
help identify therapeutic targets to enhance bone regeneration.
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1.1.2 PDGF ligands, receptors and intracellular signaling
PDGF Ligands
PDGF was first identified by Ross et al

(35)

in serum as a principle mitogen for mesenchymal

cells. It is usually stored in a-granules of platelets and released during platelet degranulation at the site of
vascular injury(36). PDGF plays an essential role in tissue repair, both as a stimulant of cell growth and a
chemoattractant to cells involved in the repair process(37). The sources of PDGF during wound repair
include platelets, smooth muscle cells, macrophages and endothelial cells.(3,38)
The original impetus for investigating the role of PDGF-BB in bone repair arises from its native
presence in the fracture site(39,40). As mentioned earlier, the initial stage of fracture healing involves the
formation of hematoma with the occurrence of inflammation. The function of hematoma is considered to
be a source of signal molecules, initiating the cascade of cellular events(7). Inflammatory cells secret
cytokines such as monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6), clearing cellular
debris and promoting the recruitment of new blood vessels. Degranulating platelets in the clot release
molecules such as TGFb and PDGF, triggering the activation and proliferation of skeletal progenitor
cells(3).
There are five family members of PDGFs (PDGF-AA,-BB,-AB,-CC,-DD), among which PDGFBB is considered the universal isoform because it can bind to all the isoforms of PDGFR(41). PDGF is
synthesized by a variety of cell types including platelets, macrophages, osteoblasts and fibroblasts.
Among these, megakaryocytes, vascular endothelial cells and neurons are the major sources of PDGFBB. PDGF-AA and PDGF-CC are synthesized by neural progenitor cells, epithelial cells and muscle. The
secretion of PDGF-DD has been reported in fibroblasts and vascular smooth muscle cells (VSMCs) in
vitro(41). During fracture, the concentration of PDGF increases following platelet aggregation and could
induce expansion of osteoprogenitor population(42).

7

PDGF Receptors
PDGF exerts its effects by binding to receptors on the surface of target cells. PDGF receptors
(PDGFRs) belong to the family of receptor tyrosine kinases (RTKs). There are two different PDGFR
chains: PDGFR-α and PDGFR-β, which are transmembrane proteins of 170 and 180 kDa respectively.
Each receptor contains five extracellular immunoglobulin-like domains, and two intracellular tyrosine
kinase domains containing a specific sequence of PDGFR(41). The binding of PDGF leads to dimerization
of the receptors, forming: PDGFRaa homodimer, PDGFRbb homodimer or PDGFRab heterodimer.
Different isoforms of PDGF have different binding capacities to the receptors(43). The possibility of
PDGF-PDGFR interactions is complex as shown in Figure 1.2A.
Despite the similarities between two different receptors, there is a significant difference in the
phenotype of mice lacking either PDGFRα or PDGFRβ(44). PDGFRα is required for neural crest cell
development and normal patterning of the somites(45);

PDGFRβ deficient mice had hematological

disorders and died perinatally due to abnormal kidney development by a lack of mesangial cells(46).
PDGFRb also plays a role during craniofacial development in mice and the two receptors form functional
heterodimers with distinct signaling properties (47). PDGFRα and β are not expressed at the same time and
locations during development, suggesting that the expression of these receptors is regulated by different
mechanisms(44).
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Figure 1.2. PDGF binding and signaling pathways.
(A) PDGF-PDGFR interactions proven in vitro. Weak interactions or conflicting reports are
represented with dashed line. (B) Simplified representation of main signaling pathways after
PDGF-BB binding and interactions with the cytoskeleton and integrin. Reprinted from Eur Cell
Mater. 2017 Jul 17;34:15-39(48)
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PDGF Signaling
As with other growth factor-receptor interactions, PDGF ligand binding leads to the auto
phosphorylation of receptors which subsequently activate downstream signaling(38). Several pathways
have been discovered to actively participate in many cellular responses upon the treatment of PDGF(48,49).
Mitogen-activated protein kinases (MAPKs) are a family of serine/threonine kinases which include
extracellular signal-regulated kinase (ERK), p38 MAPK and c-jun N-terminal kinase(JNK), all of which
are involved in PDGF-stimulated proliferation and migration(50). In addition, phospholipase C-g (PLC-g)
and phosphatidylinositol 3-kinase (PI3K)/Akt are also downstream signaling of PDGF and PI3K is more
specific to PDGF response than MAPK(51,52). (Figure 1.2B)
An early study on the MC3T3 osteoblast cell line showed that the mitogenic response of PDGFBB was dependent on ERK and JNK signaling, whereas the migratory response was dependent on p38
MAPK and JNK(50). In human mesenchymal stromal cells (hMSC), on the other hand, PDGFRβ signaling
is proposed to regulate MSC self-renewal through two distinct pathways: Akt to induce proliferation and
Erk to prevent differentiation(53). There is limited information, however, regarding the effects and
signaling pathway utilized by PDGF on periosteal derived cells.
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1.1.3 Role of rhPDGF-BB in orthopedic bone regeneration
rhPDGF-BB in clinical application
Recombinant human PDGF-BB (rhPDGF-BB) has been explored for orthopedic bone
regeneration in several conditions. The development of GEM 21S, which comprises an osteo-conductive
scaffold of b-tricalcium phosphate (b-TCP) and rhPDGF-BB, was approved by the Food and Drug
Administration (FDA) for the use of periodontal bone regeneration(43,54). In a pivotal, randomized,
controlled blinded clinical trial, GEM 21S treatment in large periodontal bone defects resulted in
significantly faster tissue attachment and increased bone regeneration at 6 months(55). An identical
product: Augment Bone Graft (Augment) (rhPDGF-BB combined with b-TCP), is also developed as an
alternative to autologous bone graft in the fusion of hindfoot and ankle joints. The clinical success was
also observed in multicenter trials(56).
The average dose of rhPDGF-BB in Augment used for clinical trials is 1.8mg, with the maximum
dose as 1.5 times more(54). The safety of rhPDGF-BB has also been demonstrated in a variety of studies
on the pharmacokinetic release, chronic toxicity and carcinogenicities in rats and dogs. These studies
showed that systemic exposure of rhPDGF-BB was brief and clearance was rapid. Most importantly, there
is no report so far associating use of rhPDGF-BB with serious device-related adverse events,
immunologic sequelae, or other negative reactions in clinical trials.

PDGF in experimental studies
Although PDGF has been approved for clinical applications(57), its effects on osteogenic
differentiation and long bone formation are not fully understood. In vitro studies suggest the response to
PDGF to be cell type dependent (Table 1.1). While a mitogenic effect of PDGF was observed
consistently in osteoblastic lineage cells, their impact on osteogenic differentiation is unclear. PDGF
seems to either inhibit or has no effect on osteogenesis of different cell lines or primary human/ murine
cells(58-60). There is only one study demonstrated that PDGF-AA could enhance osteogenic differentiation
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of mouse MSCs(61), although no effect was reported in another study(62). To date, the effect of PDGF on
periosteal cells has not been studied.
More efforts were made to explore the in vivo effects of PDGF on bone regeneration. As
summarized in Table 1.2, multiple mouse models with different carrier and doses of PDGF have been
explored. The most common model examined is the critical defect in rats, often combined with surgery to
induce osteoporosis. Using different carriers and doses of PDGF, various outcomes have been observed.
In an early study, osteotomized tibia of rabbits was injected with 80µg PDGF in 0.15ml collagen(63). After
4 weeks, increased callus stiffness and strength and more callus formation was found comparing with
control. When 0.3mg/ml PDGF-BB in the presence of b-TCP/bovine bone mineral matrix was delivered
into rat calvarial defects(64), no effect was demonstrated. There are very few studies so far exploring the
effects of PDGF on fracture healing in healthy mice (will be discussed in Chapter 3).
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Table 1.1: Summary of in vitro studies on PDGF effects in osteoblastic lineage cells ( increase; decrease)
Cell types

PDGF isoforms

Assays

Conclusions

Reference

Rat calvarial cells

PDGF-BB

3H-thymidine,
3H-proline

bone DNA synthesis

Canalis, 1981(58)

Rat calvarial cells

PDGF-BB

Von Kossa

osteogenic differentiation

Yu, 1997(65)

hBMSC

Platelet supernatant
(PDGF neutralizing
Ab)

ALP stain/activity

hMSC

PDGF

Von Kossa, Alizarin Red

Rat osteoblasts
MC3T3E1

Imatinib
(Tyrosine kinase
inhibitor)

Von Kossa

Mouse BMSC

PDGFRbdel/del

ALP stain/activity

PDGFRbdel/del enhances osteogenesis,
inhibits proliferation and migration

Tokunaga,
2008(62)

MC3T3E1, hMSC

PDGF-AB

OPG

OPG production

McCarthy,
2009(67)

Mouse MSCs

PDGF-AA

Von Kossa, Alizarin Red

osteogenic differentiation

Li, 2014(61)

hMSC, hASC

PDGF-BB

Von Kossa, Alizarin Red

MG-63 osteoblasts

PDGF-BB/BMP2Heparinized-Ti

ALP, Ca contents,
Osteocalcin and osteopontin

proliferation, migration

Gruber, 2004(59)

osteogenic differentiation
PI3K signaling
Imatinib
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osteogenesis

differentiation,
proliferation, apoptosis,
osteoclastogenesis

No effect on MSC osteogensis
ASC osteogenesis
Subtle additive effects on ALP and Ocn
expression

Kratchmarvova,
2005(51)
O’Sullivan,
2007(66)

Huang, 2015(60)
Kim, 2015(68)

Table 1.2: Summary of in vivo studies on PDGF effects on bone regeneration
Mouse Model

PDGF doses

Carrier

Assessment

Conclusions

Reference

Tibial osteotomies in
rabbits

80µg PDGF-BB

collagen matrix

XR, mechanical test,
histology

callus density and volume

Nash, 1994(63)

Ovariectomy (OVX)
in rats

2mg PDGF-BB or
0.075mg alendronate
3 times/week for 6 wks

iv. injection

µCT, histology,
mechanical test,
DXA

bone density and strength;
co-administer with alendronate
further enhance

Mitlak, 1996(69)

Geriatric
osteoporotic rats

0.3mg/ml or 1mg/ml
PDGF-BB

b-TCP/collagen
matrix

µCT, histology,
mechanical test

strength parameters
@5 weeks

Hollinger,
2008(70)

Tibia Fracture in
mice

PDGFRbdel/del

Diabetic fracture
model in rats

rhPDGF-BB
Low dose: 22µg
High dose: 75µg

b-TCP/collagen
matrix

Mechanical test

Femur defect in rats

5µg,15µg,50µg
rhPDGF-BB weekly for
4 weeks

collagen matrix

XR, µCT, histology

new bone formation
@7 weeks

Moore, 2009(72)

Calvarial defect in
rats

50ng PDGF-BB,100ng
BMP2

Fibrinogen

µCT

No effect on bone healing

Martino, 2011(73)

Critical defects in
osteoporosis (OVX)
rats

BMP7+ PDGF-B

Porous scaffolds
bioglass/silk

µCT, histology

BMP7+ PDGF-B
bone volume@ 4wk

Zhang, 2012(74)

histology
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cartilage

bone on D7

strength parameters @8wks
(low dose)

Tokunaga,
2008(62)
Loay Al-Zube,
2009(71)

Table 1.2:

Summary of in vivo studies on PDGF effects on bone regeneration (continued)

Critical defect in
rats

250ngPDGF-BB/
10µg BMP2

Fibrinogen+thrombin
(fibrin clots)
Silicon spacer 1st 4wks,
then add growth factors
for 4wks

Critical defect in
rats

AdBMP2 transfected
BMSCs+
10µgPDGF/defect

200µl of 1% Collagen
hydrogel

Bone marrow
transplantation

PDGFB transfected
hematopoietic stem
cells (HSC)

Calvarial defect in
rats

0.3mg/ml PDGF-BB

b-TCP/bovine bone
mineral matrix
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BMP2

bone healing

Bone volume;
union rate (µCT)

Bone volume
BV/TV, BMD(µCT)

BMSCBMP2 and
BMSC
/PDGF bone healing;
No difference between two

Park,
2013(76)

µCT, histology

PDGFB transfected HSC
bone formation

Chen,
2015(77)

histomorphometry

No effect on bone formation

Luvizuto,
2016(64)

PDGF-BB has no effect

BMP2

Kaipel,
2012(75)

1.1.4 The crosstalk between RTK and BMP signaling
BMP2 signaling
Bone morphogenetic protein 2 (BMP2) has been extensively studied for the therapeutic use of
bone regeneration. It was originally discovered from demineralized bone matrix which can induce
osteogenic differentiation(78,79). Since then, numerous studies have demonstrated its osteoinductive
potential in vitro and in vivo(80).
BMPs belong to the transforming growth factor-b (TGF-b) superfamily which include TGFb, Activin, BMPs and other related proteins(81). Like other members of the family, BMPs signal through a
heterometric receptor complex comprised of type I and type II receptors. BMP receptors belong to
serine/threonine kinase receptors and there are three subclasses of type I receptors (type IA/ activing
receptor-like kinase (ALK)-3, type IB/ALK-6 and type I activing receptor (AcvR1/ALK2).
Upon ligand binding, type I receptor phosphorylates and activates type II, initiating downstream
signaling. The canonical BMP2 signaling is transduced through Small mothers against decapentaplegics
(Smad) proteins. Activated receptors phosphorylate Smad1, Smad5, and Smad8 (Receptor-regulated
Smads:R-Smads), which then interact with co-Smad (Smad4) and translocate into the nucleus to regulate
target gene expression(82). Additionally, a Smad independent pathway induced by BMP2 results in the
induction of the p38 MAPK pathway. Evidence suggests that preformed receptor complexes activate the
canonical Smad signaling whereas BMP2-induced recruitment of receptors activates the non-canonical
pathway(83).
In addition, BMP signaling is also regulated by a group of protein including Noggin, Chordin,
Gremlin, Follistatin and the Dan family(84-89). These antagonists prevent the binding of ligands and
receptors, fine-tuning BMP pathway. The activity of BMPs is thus regulated with these and many other
inhibitors (intracellular or extracellular) to maintain a coordinated bone formation.
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The Role of BMP signaling in bone
The temporal and spatial expression of BMPs and BMPRs during fracture repair has been
examined in rats and mouse

(90-92)

. Immunostaining for BMP2 and BMP4 are broadly detected during

fracture healing, accompanied by the expression of BMPRs. The expression of BMPs was strongly
induced in the thickened periosteum in early stages of repair, increased later in various types of cells
including fibroblast-like spindle cells, proliferating and mature chondrocytes and newly formed trabecular
bone as well as osteoclast-like cells in the later stage. In addition, BMP type I receptors (BMPR-1A and
BMPR-1B) and type II receptor (BMPR-II) are found to co-localize during fracture repair. BMP7 seems
to exhibit a different expression pattern with high expression detected in early stage, which then
decreased. Various levels of expression in chondrocytes was also observed.
The requirement of endogenous BMP2 activity to initiate fracture healing has been discovered in
genetic studies(93). Mice lacking endogenous BMP2 expression in their limb bone mesenchymal cells
(Bmp2fl/fl; Prx1::Cre) have spontaneous fractures which never initiate a healing response. Furthermore,
observation from bone graft transplantation experiments indicated that expression of endogenous BMP2
in periosteal cells is essential for bone healing(94,95). When mutant BMP2 deficient bone graft was
transplanted into wild type mouse, undifferentiated cells were found within periosteum with significantly
less bone formation(94).

Figure 1.3. Schematic diagram of
canonical BMP2 signaling pathway.
Binding of BMP ligands induces dimerization
of type I and type II BMPRs. The BMPR-II
phosphorylates BMPR-I, which in turn
phosphorylate phosphorylates the downstream
effector
proteins
(Smad1/5/8).
The
phosphorylated Smad1/5/8 forms a complex
with Smad4 and translocates from cytoplasm
to nucleus and induces the expression of the
osteoblast-related genes.
Reprinted from Trends Biotechnol 32, 74-81(82).
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Given the dramatic osteogenic effects of BMPs in vitro, they have been extensively investigated
for therapeutic application. Two BMPs are currently approved by FDA for clinical application: rhBMP2
(InFUSE) and rhBMP7 (osteogenic protein-1)(96). Three conditions for which BMPs are clinical used
include non-union, open tibial fractures and spinal fusion(97).
Although robust response to BMP2 was observed in vitro, the effective doses of BMP required in
humans are extremely high, which is associated with high complication rates(98). While several lines of
evidence suggest enhanced bone resorption with BMP2 treatment(99-101), the limitation of human response
to BMP2 is still not totally understood. Considering the complex in vivo environment, other pathways
such as growth factor activated signaling may interfere and dampen its signaling and functions in vivo.

Signaling Crosstalk between BMP2 and RTK pathway
While Smad proteins are the main downstream mediators of BMP2 activity in bone, they also
participate in extensive crosstalk with other signaling pathways(102,103). The Wnt(104,105), Notch(106),
Hedgehog(107), Parathyroid hormone (PTH)(108), Fibroblast growth factor (FGF)(109) and Ras-MAPK
pathway(110) have all been implicated in this crosstalk. Mutagenesis studies showed that MAPK and BMP
pathways phosphorylate different Smad1 sites. MAPK catalyzes phosphorylation in the Smad1 linker
region, enabling its recognition by ubiquitin ligase Smurf1 leading to the downregulation of BMP2
signaling (111-113). On the other hand, Chan et al(114) demonstrated that PDGF-BB, which acts via RTK can
induce microRNA-24 expression in vascular smooth muscle cells, resulting in reduced expression of
Smad proteins.
RTK signaling has important roles in cell proliferation, differentiation and survival. Although the
effect of RTK on osteogenesis is still ambiguous, investigating the crosstalk between RTK and BMP
signaling in different cell types will help reveal the regulatory network that modulates BMP function.
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1.2 Hypothesis and Specific Aims
Rationale and Hypothesis
Previous studies on osteoblastic cells and BMSCs consistently showed a proliferative and
migratory response to PDGF-BB in vitro(115,116). The osteogenic differentiation of these cells, however, is
inhibited by PDGF-BB but the mechanism is unknown. We observed highly expressed PDGFRs,
especially PDGFRb in intact periosteum and periosteum-derived callus during fracture. Thus, the overall
objective of this study is to evaluate the effects of PDGF/PDGFR-β signaling on the periosteal
derived cells in vitro and fracture healing in vivo. We are particularly interested in investigating the
interaction between PDGF-BB and BMP2 signaling to further understand the underlying mechanism.
Our preliminary study shows that periosteal derived progenitor cells highly express PDGFR-b in
vitro. During osteogenic differentiation, PDGF-BB inhibits the formation of mineralized nodules and the
expression of osteogenic genes of PDCs. It also inhibits BMP2-induced osteogenic differentiation,
indicating PDGF-BB as a negative modulator of BMP2 pathway. Based on above observations, we
hypothesize that PDGF-BB inhibits periosteal differentiation through down regulation of BMP2
signaling; inhibiting PDGFR-β signaling would potentiate periosteal differentiation in vitro and
regulate bone formation in vivo. We plan to approach our hypothesis in the following aims:

1.2.1 Specific Aim I (Chapter 2)
Aim 1: Investigate the mechanisms of the inhibitory effect of PDGF-BB on osteogenic
differentiation of periosteal derived cells.
Rationale and hypothesis: Our preliminary study shows that PDGF-BB inhibits BMP2-induced
osteogenic differentiation of periosteal derived cells. BMP2 exerts its osteogenic effects primarily through
the canonical Smad signaling pathway. Therefore we propose to investigate the interaction between

19

PDGF signaling and BMP2-mediated Smad signaling. We hypothesize that PDGF-BB inhibits
osteogenic differentiation of PDCs through reducing or blocking BMP2-Smad signaling.
Aim 1A

Determine whether PDGF-BB interferes with BMP2-Smad signaling in PDCs.

Aim 1B

Identify the signaling pathway utilized by PDGF-BB in the inhibition of osteogenic
differentiation of PDCs.

1.2.2 Specific Aim II (Chapter 3)
Aim 2: Evaluate the effects of inhibiting PDGF-BB/PDGFR-b signaling on osteogenic
differentiation of periosteal derived cells in vitro and in vivo.
Rationale and hypothesis: Alpha smooth muscle actin (aSMA) has been identified to label
mesenchymal progenitor cells during fracture healing(33). aSMA-labeled periosteal cells make the major
contribution to callus formation. PDGFRb is also expressed on aSMA-labeled periosteal cells during
bone healing(34), which directed us to study PDGF signaling in vivo using a conditional deletion mouse
model. We propose to cross aSMACreERT2 mice with Pdgfrbfl/fl mice to target deletion in mesenchymal
progenitor cells and hypothesize that deleting PDGFRb in PDCs will potentiate osteogenic differentiation
of PDCs in vitro and potentially enhance bone healing in vivo.
Aim 2A

Determine whether inhibiting PDGF-BB/PDGFR-b signaling would enhance osteogenic
differentiation of periosteal derived cells in vitro.

Aim 2B

Evaluate the effects of inhibiting PDGF-BB/PDGFR-b signaling on fracture healing
in vivo.
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1.3 Significance
Elucidating the molecular regulation of osteogenesis has important clinical implications for bone
regeneration. Given the complexity of signaling pathways involved in fracture healing, it is conceivable
that various types of cells respond to the stimulation of different signal cascades. Understanding the
molecular mechanisms will provide insight into possible therapeutic targets. On the other hand, the
inhibitory effects of PDGF on BMPs should also be integrated in the attempt to optimize bioengineering
strategies using both growth factors and osteogenic factors. Comparing with previous studies, the current
study also present novelties as below:
•

The thesis focuses on periosteum derived progenitor cells, which are critical population for
fracture healing. Information on the periosteal response to PDGF-BB will help us better
understand cellular events that take place during fracture healing.

•

In the attempt to investigate the mechanism of inhibiting periosteal differentiation by PDGF-BB,
we are particularly interested in its interactions with BMP2. They both have been extensively
studied, but need additional attention regarding their crosstalk.

•

We also generate a conditional PDGFRb knockout mouse model in osteoprogenitor cells using
aSMA and examined the effects in fracture healing. This is the first report on the outcome of
depleting PDGFRb in osteoprogenitor cells in fracture repair.
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1.4 Thesis outline
This thesis consists of two major studies which attempt to elucidate the role of PDGFBB/PDGFR-b signaling on periosteum mediated bone regeneration both in vitro and in vivo.
Chapter 2:

Examine the effects of PDGF-BB/PDGFR-b signaling on periosteal derived cells
in vitro. We presented the preliminary study which provides the rationale for
hypothesis and explored the specific aim I.

Chapter 3:

Develop an in vivo transgenic mouse model to investigate the role of PDGFBB/PDGFR-b signaling on fracture healing. We conditionally deleted PDGFRb in
osteoprogenitor cells and evaluated the outcome (specific aim II).

Chapter 4:

Discuss the major conclusions, implications and future directions of this study.

Overall, this thesis provides information on the PDGF as well as its interaction with BMP2
signaling in bone regeneration. These in vitro and in vivo studies will help us better understand the role
PDGF-BB plays in periosteum and provides information for further investigation.
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Chapter 2: Effects of PDGF-BB/PDGFR-b signaling
on periosteal derived cells in vitro
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Chapter 2
2.1 Introduction
PDGFs are potent mitogens for mesenchymal cells and important mediators during fracture
healing. Although the effects of PDGF have been reported in many cell types in vitro, the response of
mesenchymal progenitor cells of the periosteum to PDGF has never been studied. BMP2 has wellcharacterized roles in the osteogenesis of MSCs and plays an essential role in the initiation of periosteum
mediated fracture healing(94). Multiple signaling pathways act in an interacted manner within the cells,
and understanding interactions between growth factors and BMPs is of particular interest.
In this chapter, we aimed to evaluate the effect of PDGFR-b signaling in periosteum derived
cells. We first explored the expression pattern and frequency of PDGFRs during the course of fracture.
Using in vitro culture, the proliferation, migration and apoptosis of periosteal progenitor cells were further
examined. We also examined the osteogenic differentiation and discovered the inhibitory effects of PDGF
on BMP2-induced osteogenesis. We hypothesize that PDGF-BB inhibits periosteal differentiation
through down regulation of BMP2 signaling and further investigated the mechanisms underlying the
effect of PDGF-BB in periosteal derived progenitor cells.

2.2 Materials and Methods
Mouse strains and fractures
All animal procedures were approved by the institutional animal care and use committee at UConn
Health. All mice were maintained on a regular chow diet and kept on a 12-hour light-dark cycle. 8-12
week old female C57BL/6 mice were used for fracture studies. Closed transverse femoral fractures were
created on the right femur of 8-12 week old mice. Prior and following surgery, mice were administered
0.1mg/kg body weight buprenorphine and anesthetized by isoflurane inhalation. A 0.5-mm-diameter 25G
needle (BD) was inserted in the medullary cavity before fracture to stabilize the fracture. A drop-weight
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blunt guillotine device was used to create fracture and the mid-diaphyseal location was confirmed by Xray (Faxitron LX-60). Closed transverse tibial fractures on both tibias were performed for the flow
cytometry experiments. Briefly, a 0.4-mm-diameter 27G needle (BD) was inserted in the medullary canal
prior to fracture. Fractures were created 1 to 2 mm proximal to the distal tibia-fibula junction using the
guillotine device. X-ray was used to confirm pin and fracture placement. Mice were sacrificed on day 4
and day 10 by carbon dioxide inhalation.

Histology
Femurs or tibias were fixed in 10% formalin (Sigma) for 5 days at 4°C. The intramedullary pins were
then removed and bones were incubated overnight in 30% sucrose/PBS, and embedded in Cryomatrix
(Thermo Fisher Scientific, Waltham, MA, USA). 7µm sections were obtained on a Leica cryostat
(Wetzler, Germany) using a tape transfer system (Section-lab, Hiroshima, Japan). Following fluorescent
imaging, sections were stained with Mayer’s Hematoxylin (Sigma-Aldrich), or 0.02% Fast green
followed by 0.1% Safranin O.

Immunostaining
Immunostaining was performed on undecalcified frozen sections for PDGFRa (1:80, AF1062, R&D
Systems) and PDGFRb (1:100, MA5-15143, Thermo Scientific). Frozen sections were rehydrated in PBS
and blocked with Powerblock (Biogenex, Fremont, CA) for 10 mins. After blocking, sections were
incubated with primary antibody (diluted in PBS 0.1% BSA) overnight at 4°C. After washing, secondary
antibodies (for PDGFRa: donkey anti-goat Alexa Fluor 647 diluted in 1:500; for PDGFRb: goat antirabbit Alexa Fluor 647 diluted in 1: 200) were applied for 1 hour at room temperature. For PDGFRb:
sections were incubated in citrate-based Antigen Unmasking Solution at 60ºC (Vector Laboratories,
Burlingame, CA) for 10 hours before blocking. Images were acquired on an Axioscan microscope (Carl
Zeiss, Thornwood, NY, USA).

25

Flow Cytometry and cell sorting
Intact periosteum or calluses pooled from fractured tibias of 2 mice were isolated to perform cell surface
marker analysis. Tibias were dissected free of muscle and connective tissue. Epiphyses were then
removed and bone marrow was flushed. The periosteum or periosteal callus was scraped and
enzymatically digested for 1h at 37ºC on an orbital shaker (0.05% collagenase P, 0.2% hyaluronadase in
PBS). Cell surface marker analysis was performed using commercially available antibodies (Table 2.1).
1X Hank’s balanced salt solution, 10mM HEPES, 2% fetal bovine serum (FBS) were used as staining
medium. After incubation with secondary antibody (when applicable), cells were stained with Live/Dead
Fixable Near-IR Dead Cell stain (Life Technologies, Carlsbad, CA, USA). Cell sorting and analysis was
performed using a FACSAria II or LSRII (BD Biosciences, San Jose, CA, USA). Gates were set based on
unstained samples, single stained controls, isotype controls and fluorescence minus one (FMO) controls.

CFU-F and CFU-ALP assays
Freshly isolated periosteum derived cells were gated on CD45/Ter119/CD31- population. These cells
were further separated based on the expression of PDGFRa and PDGFRb. Cells were seeded at a density
of 500 cells/well in 6-well plates in triplicates and maintained in Minimum Essential Medium alpha
modifications (aMEM)+20%FBS. Cells were cultured in 5% oxygen for 9-10 days with half medium
replaced on day 4, then fixed in 10% formalin, and stained with crystal violet solution. Crystal violet
stained colonies were counted for assessment of CFU-F. For CFU-ALP assay, sorted cells were seeded at
density of 2500 cells/well in 12-well plates, cultured in aMEM+20% FBS for 9 days, then osteogenic
medium (50 µg/ml of ascorbic acid, 4 mM of b-glycerophosphate) for 14 days.

Periosteal Derived Cells Culture
Femora and tibiae from 6-8 week old C57BL/6 or Col2.3GFP mice were dissected free of muscle and
connective tissue. The Col2.3GFP mice were previously described(117). Epiphyses were then removed and
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bone marrow was flushed. The periosteum was scraped by scalpel and enzymatically digested for 1h at
37ºC on an orbital shaker (0.05% collagenase P, 0.2% hyaluronadase in PBS). The cell suspension was
then filtered through a 40µm nylon mesh (BD Falcon). Following washing, 5x104 cells/cm2 were seeded
in growth medium (aMEM+10%FBS+ Pen/Strep) and cultured in 5% oxygen for the first 4 days. Half
medium was changed on day 4 and cultures were then incubated in ambient oxygen. Cells usually reach
confluence after 7 days and primary or passage one cells were used for experiments depending on
experimental design.

Proliferation assay
The proliferation of PDCs was measured by EdU assay. Passaged PDCs were seeded at a density of 5x104
cells/cm2 in 6-well plates in growth medium and allowed to attach overnight. Growth medium was then
removed, and cells were incubated with Dulbecco’s modified eagle medium (DMEM) containing 0.5%
FBS with or without Recombinant Rat PDGF-BB (R&D Systems) (Table 2.2) for 20 hours. Cells were
treated with 10µM 5-ethynyl-2’-deoxyuridine (EdU) for 4 hours and then harvested by trypsinization and
stained with the Click-It EdU Alexa Fluor 647 cell proliferation assay kit (Invitrogen, ThermoFisher) as
per manufacturer’s instruction. The number of EdU-positive cells was determined by flow cytometry and
data analysis was performed using DIVA software (Becton Dickinson Biosciences, San Jose, CA).

Transwell assay
The migration of PDCs was performed using transwell cell culture inserts (8.0um pore size; BD Falcon,
fisher scientific) for 24-well plates. 5X104 cells in 300µl of serum free media were seeded into upper
chamber. The lower chamber contained 1ng/ml or 10ng/ml PDGF-BB and serum free media served as
control. Cells were incubated @ 37ºC for 24 hours and those remained on the upper membrane were
removed with cotton swabs. Cells that migrated through the membrane were stained with crystal violet.
The number of migrated cells was counted in 5 random fields at 100X magnification.
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Scratch assay
Cell migration was also measured by scratch assay to mimic wound healing(118). Passaged PDCs were
plated in 60mm dish and incubated in normal growth medium (aMEM+10%FBS+Pen/Strep). After
reaching confluence cells were starved in 0.5% aMEM medium for 12 hours and scratched with a plastic
pipette tip. After a gentle wash with PBS, cells were treated with 10ng/ml PDGF-BB and incubated for 48
hours. Wound closure was observed under an inverted microscope at different time points (12, 18, 30, 48
hours) and the migration was evaluated by measuring the distance between wound site. At least three
different areas were followed and quantified for each group. Cell migration was represented as the
migrated distance divided by the original wound distance in each group (% of wound closure) at each
time point. Images were quantified in Fiji image analysis software.

TUNEL assay
Passaged PDCs were seeded at a density of 3x104 cells/chamber on 8-chamber slide in 300µl growth
medium. After 48h, they were starved in 0.1% BSA for 72 hours and then treated with 10ng/ml PDGFBB for 12 hours. After treatment, the Click-iT plus TUNEL Assay (Alexa Fluor 647) was utilized
according to the manufacturer’s instructions (Life Technologies, ThermoFisher). DNase treatment was
performed as a positive control. The cells were counterstained with Hoechst 33342 (Invitrogen,
ThermoFisher) and TUNEL positive nuclei were counted in ImageJ. For quantification, apoptotic cells
were represented as the percentage of TUNEL+ nuclei.

Osteogenic differentiation
Primary PDC were seeded in 12-well plates and cultured in growth medium for 7 days and then induced
towards osteogenic differentiation (50 µg/ml of ascorbic acid, 4 mM of b-glycerophosphate) for another
14 days. Growth factors were added as indicated in experimental design. Medium with growth factors
was changed every two days. Col2.3GFP expression were detected using a Zeiss Oberver Z.1 inverted
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microscope and whole wells images were scanned for quantification. Cells were stained for alkaline
phosphatase (ALP) staining using a commercially available kit (Sigma-Aldrich) according to
manufacturer’s instructions.

Quantitative RT-PCR
Cells were lysed with Trizol (Thermofisher), and RNA was extracted as per manufacturer’s instructions.
1µg RNA was treated with DNase (Invitrogen, Carlsbad, CA) and reverse transcribed to generate cDNA
using the ImProm-II Reverse Transcription kit (Promega). Real time PCR were performed with 1µM final
primer concentration in SYBR Green PCR Master Mix (Applied Biosciences, Life Technologies) on the
Applied Biosystems 7900 HT instrument (Life Technologies). PCR cycles: 50ºC for 2 min, 95ºC 10min,
followed by 40 cycles of 95ºC 15 sec, 60ºC 1 mins, and final melting curve step to confirm signal
specificity. Expression of differentiation marker genes was determined by Taqman assay. Commercial
Taqman primers as used with Taqman Universal PCR Master Mix (Applied Biosystems, Life
Technologies). Primer sequences for the genes examined are shown in Table 2.3. Gene expression level
was normalized by GAPDH and expressed as relative fold change comparing with control group using the
DDCt method.

Western Blots
Passaged PDCs were seeded in 6-well plate and serum starved after 70-80% confluence. Cells were then
treated with PDGF-BB (10ng/ml) and/or BMP2 (100ng/ml) for 20-30 mins and whole cell lysates were
lysed in mRIPA buffer containing 0.1% SDS and proteinase phosphatase inhibitor cocktail (Thermo
Fisher Scientific). Protein concentration was measured using Pierce BCA Protein Assay Kit (Thermo
Fisher Scientific). Equal amount of proteins from 20-40ug were separated on 4-15% SDS-PAGE gel
according to standard protocols and transferred to PVDF membranes. The membrane was incubated in
blocking buffer (5% BSA in TBST) for 60 mins and immunoblotted with the primary antibody overnight
at 4ºC. Secondary antibodies conjugated with horseradish peroxidase were then applied for 1 hour at
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room temperature. Antibodies used for western blots are shown in Table 2.4. Protein bands were detected
using Pierce ECL substrate (Thermo Fisher Scientific) and imaged on the Molecular Imager Gel Doc
XR+ machine (Bio-Rad). The amount of protein in individual bands was quantified with Image Lab
Software (Bio-Rad). For reprobing, the blots were stripped in stripping buffer containing and blocked
again before immunoblotting the antibodies.

Immunocytochemistry
Passaged PDCs (3x104 cells) were plated on glass coverslips and treated with ERK1/2 inhibitor U0126
(10µM) or PI3K inhibitor LY294002 (10µM), or DMSO for 1 hour after serum starvation. Cells were
then treated with PDGF-BB (10ng/ml) and/or BMP2 (100ng/ml) for 30 min. Cells were fixed in 4%
paraformaldehyde for 5 min at room temperature, washed in PBS and blocked in 5% goat serum with
0.3% Triton-X-100 for 1 hour. Anti-pSmad1/5/8 (Cell signaling, 1:400) was applied overnight. After
washing, cells were incubated with goat anti-rabbit Alexa Fluor 488 (Life Technologies, 1:500) for 2
hours at room temperature. Cells were counterstained with 4’,6-diamidino-2-phenylindole (DAPI) and
mounted on glass slides prior to imaging on Leica fluorescent microscope. The percentage of pSmad
positive nuclei were counted for quantification.

Image analysis and quantification
Images were analyzed using Fiji image analysis software (NIH). Briefly, RGB images were split into
single color channel 8-bit images, and region of interest (ROI) of the same size were drawn on each
image. For GFP quantification: The threshold was set for the green channel 8-bit images to further
analyze GFP positive area. The positive area fraction was calculated as the ratio of the positive area to the
total ROI area.
For apoptosis: after adjusting the threshold of Hoechst 33342 on the blue channel, the “watershed”
function was applied to separate individual nucleus. The size and circularity were then determined to
define single nucleus and images were redirected to the red channel for TUNEL signal. TUNEL positive
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cells were summarized after applying “analyze particles” function, and apoptotic cells percentage was
presented as ratio of TUNEL+ nuclei numbers to total nuclei numbers in the ROI measured. Similar
method was used for the quantification of immunocytochemistry.

Statistical Analysis
Results were analyzed using either unpaired student’s t-test for comparison between two groups or oneway ANOVA with Turkey’s post-hoc test for comparison between multiple groups using GraphPad
Prism. Data are presented as mean ± SD. p-values < 0.05 were considered statistically significant.
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2.3 Results
2.3.1 PDGFRb is expressed on the periosteum during fracture repair
We first examined the expression of PDGFRs in intact periosteum by immunostaining. As shown
in Figure 2.1, PDGFRb is detected on cells in the periosteum, endosteum and bone marrow of intact
femur. They are also expressed in the epiphyseal and metaphyseal area, but not in growth plate. Higher
magnification image shows the location of PDGFRb on the surface of individual cell. We can hardly
detect PDGFRa on the intact periosteum by immunostaining (data not shown).
PDGF/PDGFR signaling is involved in the early stage of fracture healing(41) , therefore we
observed the expression of PDGFRs on day 4, the inflammatory stage, as well as day 10 when
cartilaginous callus is formed. Four days after femur fracture, the population of PDGFRb expressing cells
increased within the thickened periosteum and in the newly formed callus around the fracture site (Figure
2.2). High signal was noticed in the bone marrow at the insertion site of the pin, indicating the cellular
response to the injury.

32

Figure 2.1. Representative images of PDGFRb expression on the intact periosteum.
(A). Frozen section of intact femur was stained with anti-PDGFRb (Red: Alexa Fluor 647) and
DAPI (blue). Periosteal area was magnified in (B). (B). PDGFRb cells were detected on
periosteum, endosteum and bone marrow and PDGFRb was expressed on cell surface (magnified
image showing representative single cell on the periosteum). The same section was stained by
Hematoxylin. PO= periosteum, CB= cortical bone, BM= bone marrow.
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Figure 2.2. Representative images of PDGFRb expression on the periosteum on Day 4 post
fracture.
(A). Frozen section of fractured femur was stained with anti-PDGFRb (Red: Alexa Fluor 647) and
DAPI (blue). Dashed lines indicate fracture site. Notice the high signal at the insert site of the pin
showing the response to injury. Thickened periosteum was magnified in (B). Periosteal callus was
magnified in (C). Representative single cell in the callus was shown in magnified image in (C):
PDGFRb was expressed on the cell surface. The same section was stained by Hematoxylin. PO=
periosteum, CB= cortical bone, BM= bone marrow.
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Ten days after fracture, the mesenchymal cells at the fracture site proliferated and differentiated
into a callus containing both cartilage and bone. Immunostaining demonstrated that PDGFRb was broadly
expressed within the callus, with the exception of the chondrogenic lineage (Figure 2.3A). We detected
fewer cells expressing PDGFRa, with a similar location as PDGFRb+ cells (Figure 2.3B).

Figure 2.3. Representative images of PDGFR expression on the periosteum on Day 10 post
fracture.
(A). Representative images of PDGFRb expression in femurs 10 days post fracture. Upper panel: frozen
sections were stained with Safranin O/fast green. Middle panel: magnified box indicating callus area.
Lower panel: the same section was stained with anti-PDGFRb (Red: Alexa Fluor 647). Arrowheads show
representative PDGFRb+ cells. Similar detection for PDGFRa expression is shown in (B). Scale
bars=1000µm.
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To quantify the frequency of PDGFR+ cells on the periosteum during fracture, we further
performed flow cytometry to analyze the expression of PDGFR on isolated cells. To obtain enough cells
for flow analysis, tibia fractures were created on both legs of 8-10 week old mice. Unfractured periosteum
and callus periosteum from day 4 and day 10 fractures were collected for analysis (Figure 2.4A). Cells
were released by enzyme digestion and immediately stained with antibodies.
Mesenchymal populations are usually defined as cells negative for hematopoietic markers such as
CD45, Ter119 or endothelial marker CD31(119). Therefore, we analyzed periosteum derived cells based on
this gating. Consistent with histological observation, within the non-hematopoietic/endothelial lineage
populations (CD45/Ter119/CD31)- of intact periosteum, around 30% of cells express either one or both
PDGFR. Following fracture, there was a significant increase in the proportion of PDGFRa-b+ cells from
around 8% to 20%. We observed very few only PDGFRa+ cells (less than 5%) in periosteum or fracture
callus, and most PDGFRa+ cells co-expressed PDGFRb (Figure 2.4B-D).
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Figure 2.4. Analysis of the frequency of PDGFR+ cells in on the intact periosteum or periosteal
callus by flow cytometry.
(A). Experimental design: tibia fracture was created on 8-10 week old mice. Unfractured periosteum was
collected on day 0 and fractured samples were collected 4 and 10 days after fracture.
(B). Representative dot plots of flow analysis on day 10 are shown. PDGFRs expression were analyzed
-

within CD45/Ter119/CD31 population.
(C). Quantification of cell frequency at different time points following fracture. Both tibias from two mice
were pooled for each sample, n=3 samples for each group.
(D). Percentage of each cell population at each time point are presented. Values are mean ± SEM, *
p<0.05 vs control.
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2.3.2 PDGFRb periosteum derived cells form significant more colonies than b cells
To evaluate the progenitor potential of PDGFR expressing cells, we sorted cells from intact
periosteum and seeded in low density to perform the colony forming unit-fibroblast (CFU-F) assay. As
shown in Figure 2.5, PDGFRa-b+ and a+b+ populations showed significantly greater colony forming
potential than both the total CD45- population and PDGFRβ- populations, confirming the enrichment of
mesenchymal progenitor cells in PDGFRβ+ populations. To examine their osteogenic potential, sorted
periosteal cells were induced towards osteogenic differentiation for 14 days. PDGFRb- cells could not
differentiate into osteoblasts, regardless of the expression of PDGFRa (data not shown), but PDGFRb+
cells formed osteoblastic colonies indicated by alkaline phosphatase (ALP) staining (Figure 2.5).

Figure 2.5. Colony forming capacities of
periosteal derived cells based on PDGFR
expression.
(A).Representative images of CFU-F assay. Cells
isolated from intact periosteum and sorted based on
PDGFR expression from (CD45/Ter119/CD31)population. Colonies were stained with crystal
violet. (B).Quantification of the number of CFU-F
colonies from two independent sorting experiment.
(C).Representative images of CFU-ALP assay.
Sorted cells were induced to osteogenic
differentiation for 14 days. Osteoblastic colonies
were shown by ALP staining.
Values are mean± SD, * p<0.05 vs control,
** p<0.01 vs control, # p<0.01.
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2.3.3 Cultured PDCs retain the mesenchymal stem cell marker expression ex vivo
We further isolated periosteum derived cells and grew them in vitro. Cells were released using the
commonly used scraping method(1) followed by enzymatic digestion to release cells. Previous studies
have shown that hypoxia condition helps maintain the progenitor populations of mesenchymal stem
cells(26,120). In order to enrich progenitor populations, primary periosteal cultures were incubated in 5%
oxygen for the first four days and then transferred to normoxic incubator (21% oxygen) afterwards.
Periosteum derived cells grew in colonies in vitro and exhibited fibroblast-like morphology like other
mesenchymal lineage cells(1). They grow fast and
usually reach confluence on day 7 (Figure 2.6).
To further characterize PDCs in vitro, we
analyzed the cell surface marker expression by
flow cytometry. In the absence of specific
marker to identify periosteum derived cells, we
used markers previously shown to define

Figure 2.6. Representative images of PDCs in
vitro.
Isolated periosteum derived cells (PDCs) grew in
colonies (left) in vitro and reached confluence on
day 7 (right). Scale bars= 100 µM.

mesenchymal stem cell (MSC)(114,121-125) and
determined the presence of a progenitor population. Gated on CD45- primary PDCs, we observed that the
majority of cells expressed MSC markers such as Sca1, CD105, CD51 and CD90 after in vitro expansion
(Figure 2.7). In addition, isolated PDCs highly express PDGFRb (91.8%±5.7%) in vitro on day 7. There
were also around 60% cells expressing PDGFRa, the majority of which co-expressed with PDGFRb.
Consistent with in vivo data, there are very few only PDGFRa+ periosteal cells, indicating the importance
of PDGFRb signaling (Figure 2.7). Similar expression pattern was observed on passaged cells, indicating
MSC properties maintained at least after one passage. Overall, isolated primary PDCs expand fast in vitro
and contain a majority of MSCs populations as shown by cell surface marker expression.
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Figure 2.7. Cell surface markers
expression on PDCs in vitro.
(A). Flow analysis of PDCs gated on CD45 nonhematopoietic population. Red histograms
represent marker expression; blue histograms
represent unstained controls. Shown is the
representative data from four independent
experiments.
(B). Representative plots of PDGFRs expression
on primary and passaged cells.
(C).Summary of flow analysis in (A), the
percentage of positive cells is shown as the mean
± SD (n=4).
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The high proportion of periosteal cells expressing PDGF receptors (particularly PDGFRb)
indicates their responsiveness to PDGF signaling during fracture. We next aimed to examine the effects of
PDGF-BB on isolated PDCs. The complexity of signaling pathways involves regulating the proliferation,
differentiation and survival of progenitor cells, all of which are essential for fracture healing. Thus we
explored the function of PDGF in various aspects of PDCs.

2.3.4 PDGF-BB promotes the proliferation, migration and inhibits the apoptosis of PDCs.
The proliferation of progenitor cells is an essential early step for bone healing. PDGF-BB is a
well-known potent mitogen for mesenchymal lineage cells(3,38,41). To examine whether they exert the same
effect on PDCs, we evaluated the proliferative effects of PDGF-BB by EdU assay. As PDGFs are the
major mitogens in the serum (up to tens of ng/ml)(126), cells were serum starved before PDGF-BB
treatment. While 1ng/ml PDGF-BB had no detectable effects on cell proliferation, 10ng/ml PDGF-BB
significantly increased the percentage of EdU+ proliferative cells comparing with control (Figure 2.8AB).
Besides cell proliferation, the recruitment of mesenchymal progenitor cells to fracture site is
another important event during bone repair. The chemotactic response of mouse or human osteoblasts to
PDGF has been reported in various cell types (127), periosteal response to PDGF is however unknown. To
examine the potential effect of PDGF-BB on PDCs, we performed transwell assay to evaluate cell
migration. While 1ng/ml PDGF-BB promoted the migration of PDCs, their migration was significantly
stimulated by the addition of 10ng/ml PDGF-BB (Figure 2.8C-D). Thus in accordance with previous
studies in other cell types, PDGF-BB also exhibited mitogenic and chemotactic effects in PDCs. We
chose the concentration of 10 ng/ml PDGF-BB in the majority of following studies since it appears to
exhibit a prominent effect in PDCs.
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Figure 2.8. PDGF-BB enhances the proliferation and migration of PDCs.
(A). Passaged PDCs were serum starved overnight and treated with 1 or 10 ng/ml PDGF-BB for 20
hours. Cells were then incubated with EdU for 4 hours and proliferating cells were analyzed by
flow cytometry. (B). Quantification of EdU+ cells percentage. ** p<0.01 vs control. (C). Cell
migration was performed by transwell assay. The representative images of invasive cells at the
bottom of the membrane stained with crystal violet were shown. (D). The quantification of cell
migration was presented as migrated cells/field. Five random fields per group was counted. ***
p<0.001 vs control. # p<0.01.
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PDGF-BB is a well-known major molecule for would healing. We also examined the effects of
PDGF-BB in PDCs by the scratch assay, which combines the cell proliferation and migration, mimicking
the wound healing process in vitro. As shown in Figure 2.9, while cells in control group migrated around
50% of the distance after 24 hours, nearly 80% of the wound was healed in PDGF-BB treatment group.
After 48 hours, the wound was still kept open in control groups whereas it was completely healed by the
presence of PDGF-BB treatment (data not shown).

Figure 2.9. PDGF-BB promotes the wound healing of PDCs.
(A). Experimental design: confluent monolayer PDCs were serum starved overnight and then
scratched to create a wound in culture. Cells were then treated with or without 10ng/ml PDGF-BB
and followed for 48 hours. Images were taken after 12, 24 and 48 hours.
(B). Representative images of cell migration after 24 hours. Lines indicate frontier area of migrated
cells.
(C). Quantification of cell migration after 24 hours. Wound closure (%) was represented as
migrated wound distance divided by original distance. ** p<0.01 vs control.
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Cell proliferation and apoptosis are coupled events that coexisted during fracture healing(128).
Since cell survival is another contribution among the wide range of biological effects of PDGF(129), we
next investigated the influence of PDGF on apoptosis of PDCs. In addition to the mitogenic and
chemotactic effects of PDGF-BB, we also observed its anti-apoptotic effects in PDCs. 10ng/ml PDGF-BB
treatment resulted in a statistically significant decrease of TUNEL+ cells as shown in Figure 2.10,
protecting cell death induced by serum starvation.

Figure 2.10. PDGF-BB inhibits the apoptosis of PDCs.
(A). Experimental design: Passaged PDCs were induced to apoptosis by serum starving in 0.1%
BSA for 72 hours. Cells were then treated with 10ng/ml PDGF-BB for 20 hours. Apoptotic cells
were detected by TUNEL assay and positive nuclei were counted for quantification.
(B). Representative images of apoptotic cells. Blue: Hoechst 33342. Green: TUNEL(Alexa Fluor
647)
(C). Quantification of TUNEL+ cells. ** p<0.01 vs control.
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2.3.5 PDGF signaling negatively regulates osteogenesis
The direct effects of PDGF-BB on osteogenesis have been controversial and cell typedependent(3) while its effect on periosteal cells differentiation still remains unknown. We next examined
the impact of PDGF in this respect. To better visualize the osteogenic differentiation, we isolated primary
PDCs from Col2.3GFP mice, which harbor a transgene that labels mature osteoblasts(117). Osteoprogenitor
cells which do not express type I collagen at the time of isolation will turn on GFP expression later on
once they differentiate into osteoblasts. To determine the effects of PDGF-BB on osteogenesis, primary
PDCs were cultured for 7 days until confluence, then induced to osteogenic differentiation in the absence
or presence of PDGF-BB for another 14 days (Figure 2.11A). Upon treatment, osteogenic differentiation
was inhibited in a dose-dependent manner indicated by decreased bone sialoprotein and osteocalcin
expression and reduced Col2.3GFP+ area (Figure 2.11 B-D).

Figure 2.11. PDGF-BB inhibits osteogenic differentiation of PDCs dose-dependently.
(A). Experimental design: Primary PDCs isolated from Col2.3GFP mice were cultured for 7 days
then induced to osteogenic differentiation with 1 or 10 ng/ml PDGF-BB for 14 days. Medium was
changed every other day with the growth factor.
(B) Gene expression of Bone sialoprotein, (C) Osteocalcin, and (D) quantification of Col2.3GFP
#
area. Values are mean ± SD, ** p<0.01 vs control, p<0.01.
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BMPs are potent osteogenic factors for mesenchymal stem cells. BMP2 activity is also required
for periosteal progenitor cell differentiation, which drives bone healing (95,130). Given the mitogenic effects
of PDGF-BB in PDCs, we examined whether the combination of PDGF-BB and BMP2 would enhance
osteogenesis of PDCs. We chose 10ng/ml PDGF-BB in the following study since it has a clear effect on
PDC proliferation and differentiation. As expected, BMP2 (100ng/ml) treatment significantly induced the
formation of mature osteoblasts as shown by the expression of GFP as well as osteogenic differentiation
marker gene. However, this effect was suppressed by the presence of PDGF-BB (Figure 2.12).
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Figure 2.12. PDGF-BB inhibits BMP2-induced osteogenic differentiation of PDCs.
(A). Experimental design: Primary PDCs isolated from Col2.3GFP mice were cultured for 7 days
then induced to osteogenic differentiation with different growth factors for 14 days.
(B). Representative images of ALP staining on day 14 and scans of culture plates showing
Col2.3GFP expression in PDCs on day 21. (C). Quantification of ALP positive areas on day 14.
Col2.3GFP area on day 14 (D) and day 21 (E). (F-G) Gene expression of Osteocalcin and Bone
sialoprotein. Values are mean ± SD, * p<0.05 vs control, ** p<0.01 vs control, # p<0.01. Scale
bars=1000µm.
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Osteoprogenitor cells undergo three distinct stages during osteogenic differentiation in vitro:
proliferation, early differentiation, and terminal differentiation/matrix maturation(131). Since PDGF is
mitogenic while BMP2 is osteogenic, we then examined the effects of sequential combination of PDGFBB and BMP2 in PDCs. Growth factor treatment started as early as day 3 during proliferation phase
before differentiation (Figure 2.13). While as we observed in Figure 2.12, continuous treatment of
PDGF-BB inhibited osteogenesis as well as BMP2-induced differentiation in PDCs. Early treatment of
PDGF-BB from day 3 to day 7, followed by BMP2 treatment enhanced osteogenic differentiation
comparing with control group. There is no difference between BMP2 (day3-21) treatment and PDGF-BB
(day3-7) + BMP2 (day 8-21) group, as shown by Col2.3 GFP expression. In addition, temporal treatment
of PDGF from day3-7 did not affect cell differentiation comparing with control.
Taken together, these data indicate that PDGF-BB negatively regulate osteogenic differentiation
of periosteum derived cells in vitro; blocked osteogenic effect of BMP2 in the presence of PDGF suggest
that PDGF-BB may act as a negative regulator of BMP2 signaling in PDCs. The signaling of PDGF-BB
seems to be transient and short term, as withdrawal of PDGF-BB recovered osteogenic differentiation of
PDCs and sequential treatment of both factors did not inhibit periosteal osteogenesis.
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Figure 2.13. Sequential combination of PDGF-BB and BMP2 enhances osteogenesis of PDCs.
(A). Experimental design: Primary PDCs isolated from Col 2.3GFP mice were cultured for 7 days
then induced to osteogenic differentiation with different growth factors for 14 days. Treatment
started on day 3 as indicated in different groups.
(B). Representative culture plates showing Col2.3GFP expression in PDCs on day 21.
(C). Quantification of Col 2.3GFP area on day 21.
Values are mean ± SD, ** p<0.01 vs control, # p<0.01. Scale bars=1000µm.
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2.3.6 PDGF-BB inhibits canonical BMP2-Smad signaling
To understand the mechanism underlying the negative regulation of osteogenic differentiation by
PDGF-BB, we investigated its effects on BMP2 signaling and downstream targets. The major effect of
BMP2 is mediated via canonical Smad pathway. Binding of BMP2 with its receptors (Type I and Type II
complex) activates the phosphorylation of RSmads (Smad1, 5, 8), which then form a complex with
Smad4 and translocate into the nucleus regulating target gene expression(103). We thus assessed the
phosphorylation of Smad1/5/8 in response to BMP2 and PDGF-BB in PDCs. As shown in Figure 2.14,
Smad1/5/8 was rapidly phosphorylated after 20 mins by BMP2 in PDCs, while this effect was reduced in
the presence of PDGF-BB. Similar effect was observed after 30 mins.

Figure 2.14. PDGF-BB inhibits canonical BMP2-Smad signaling in PDCs.
(A). PDCs were treated with 10ng/ml PDGF-BB and/or 100ng/ml BMP2 for 20 or 30 minutes and
cell lysates were separated by SDS-PAGE and, blots were probed antibodies indicated. The gels
presented are representative of three experiments.
(B). Quantification of western blot bands intensity.
Values are mean ± SD, ** p<0.01 vs control, # p<0.01.
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To further investigate the interaction between these two pathways, we examined the regulation of
PDGF-BB on BMP2 target genes expression. We treated PDCs with growth factors for 24 hours and
examined BMP2-target gene expression at different time points. BMP2 target genes include several
transcription factors that play an essential role in osteogenic differentiation such as Dlx5. It contains a
homeobox domain and has been shown to be an early BMP2 responsive gene(132). In PDCs, BMP2
quickly induced Dlx5 expression after 2 hours, which was significantly blocked by PDGF-BB (Figure
2.15).
Id1 is another well characterized downstream target of BMP2-Smad1/5/8 signaling(133,134). BMP2
immediately induces Id1 expression in various cell types and the effect is strongly dose-dependent. To
assess this response in PDCs, we also evaluated Id1 mRNA levels at different time points after BMP2
addition. As shown in Figure 2.15, Id1 expression was strongly induced by BMP2 to nearly 20 folds after
2 hours and decreased thereafter. Although BMP2-mediated up-regulation of Id1 was not affected by
PDGF-BB at 2 hours, it was significantly blocked after 24 hours. It is possible that strong response
induced by 100ng/ml BMP2 overcame the inhibitory effect of PDGF at early time point.
Alkaline phosphatase (ALP) is a widely accepted marker of differentiating osteoblasts. It has
been discovered for more than twenty years that BMP2 treatment increases Alp mRNA expression and
ALP activity(135,136). While in PDCs there was no change in gene expression after 2 hours, BMP2
significantly induced Alp expression after 24 hours which was also blocked by PDGF-BB. PDGF alone
also seemed to inhibit the Alp expression as shown in Figure 2.15.
The activity of BMP2 is also regulated by a variety of inhibitors such as Noggin and Gremlin.
They are glycoproteins which can bind and block BMP action. BMP2 can induce a time and dose
dependent expression of Noggin and Gremlin in osteoblast cells(84,85). Thus we also examined the
expression of BMP2 antagonists in PDCs. While Gremlin expression was not detected in PDCs (data not
shown), we observed a quick and strong response of Noggin expression in response to BMP2 treatment.
The basal level of Noggin expression was low in PDCs, however more than 5-fold increase of Noggin
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mRNA level was detected after 2 hours, which increased later to nearly 20-fold. This effect was
significantly blocked by PDGF-BB.

Figure 2.15. PDGF-BB inhibits BMP2 target gene expression in PDCs.
(A) Experimental design: passaged PDCs were treated with PDGF-BB and/or BMP2 for 24 hours
after serum starvation. The mRNA level of gene expression was assessed by qRT-PCR at different
time points. (B-E) Gene expression of Dlx5, Id1,Alp and Noggin at 2 and 24 hours after treatment
of PDCs. The average expression of untreated control was normalized to 1.
Values are mean ± SD, * p<0.05 vs control, ** p<0.01 vs control, # p<0.01.
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The negative effects of PDGF-BB on BMP2 mediated action may also due to its regulation on
endogenous BMP2 activity(62,76). Thus we examined whether PDGF-BB regulates endogenous BMP2 as
well as BMPRs expression in PDCs. Two types of BMP receptors (type I and type II) with two subtypes
of type I receptor (Bmpr1a and Bmpr1b) have been reported to be expressed by mesenchymal cells. The
Bmp2 expression was inhibited by PDGF-BB after 24 hours while Bmpr1a and Bmpr2 expression were
not affected (Figure 2.16). Bmpr1b was not detected in PDCs. Overall, we observed no significant
regulation on endogenous BMP2 receptors by PDGF-BB. Taken together, these results indicate inhibitory
effects of PDGF-BB on BMP2-Smad signaling targets in PDCs.

Figure 2.16. Endogenous BMP and BMPRs expression was not affected by PDGF-BB.
(A-C) Passaged PDCs were treated with PDGF-BB and/or BMP2 for 24 hours after serum
starvation. The mRNA level of gene expression was assessed by qRT-PCR at different time points.
Gene expression of Bmpr1a,Bmpr2 and Bmp2 at 2 and 24 hours after treatment of PDCs. The
average expression of untreated control was normalized to 1. Values are mean ± SD. * p<0.05 vs
control, # p<0.01.
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2.3.7 ERK1/2 MAPK and PI3K/AKT pathway is involved in PDGF-BB/PDGFRb signaling
of PDCs.
Binding of PDGF with its receptors initiate a complex signal cascade and numerous signals have
been reported to be activated by PDGF-BB in mesenchymal cells. Some include Ras-MAPK, PI3K, PLCγ and JAK(38). We chose to examine the activity of ERK1/2 MAPK and PI3K/AKT, two common
pathways involved in receptor tyrosine kinase signaling, in PDGF-BB treated PDCs using western
blotting. As shown in Figure 2.17, PDGF-BB stimulation resulted in the phosphorylation of ERK1/2 as
well as AKT pathway in PDCs. We also examined the effects of BMP2 on MAPK signals. Although there
is report on the activation of MAPK by BMP2 as a non-canonical/Smad independent pathway(85), we did
not observe the effects in PDCs under the current conditions. BMP2 also did not alter the signals by
PDGF-BB (Figure 2.17).

Figure 2.17. PDGF-BB activated ERK1/2
and AKT pathway in PDCs.
PDCs were treated with 10ng/ml PDGF-BB
and/or 100ng/ml BMP2 for 30 minutes. Total cell
lysates were immunoblotted using indicated
antibodies.
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Since PDGF-BB can activate both PDGFRa and PDGFRb receptors, we further blocked
PDGFRb signaling using a PDGFRb inhibitor, su16f

(137)

. As shown in Figure 2.18, su16f completely

blocked the phosphorylation of PDGF receptor tyrosine, as well as downstream ERK1/2 and AKT
signaling. We then examined the effects on BMP2-Smad signaling in PDCs. While PDGF-BB blocked
the phosphorylation of BMP2-induced Smad signaling, the addition of PDGFRb inhibitor su16f inhibited
effects of PDGF-BB, restoring BMP responsiveness in PDCs (Figure 2.18).
When PDGFRb inhibitor was added during osteogenic differentiation of PDCs, the inhibitory
effects of PDGF on BMP2-induced osteogenesis was also rescued, indicating that PDGFRb is the main
receptor mediating PDGF signaling in PDCs.
We further targeted the downstream signaling with specific inhibitors. The addition of ERK1/2
inhibitor (U0126) rescued the phosphorylation of Smad1/5/8 as detected in immunocytochemistry
(Figure 2.19). Since no activation of ERK1/2 was induced by BMP2 in PDCs (Figure 2.17), the rescue
effect of ERK1/2 inhibitor was specific to PDGF signaling. The addition of PI3K inhibitor (LY294002)
exhibited similar effects by rescuing inhibitory effects of PDGF-BB (Figure 2.19). We attempted to
evaluate the effect of each inhibitor during periosteal osteogenesis. Cells were unhealthy however, and
couldn’t survival very long probably due to the important role of ERK and PI3K/AKT pathway for cell
growth.
Overall, we used specific inhibitors to explore the contribution of downstream pathways in this
cellular response. At least two downstream signaling mechanisms (ERK1/2 MAPK and PI3K/AKT
pathway) are involved in PDGF-BB signaling that exerts inhibitory effects on BMP2 induced
osteogenesis in PDCs.
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Figure 2.18. PDGFRb inhibitor rescues the effects of PDGF-BB in PDCs.
(A). PDCs were pretreated with PDGFRb inhibitor su16f (5µM) for 1 hour, followed by 10ng/ml PDGFBB and/or 100ng/ml BMP2 for 30 minutes. Total cell lysates were immunoblotted using indicated
antibodies. (B). Quantification of band intensity. Values are mean ± SD, ** p<0.01 vs control, #p<0.01.
(C). Primary PDCs were induced to osteogenic differentiation on day 7 with the absence or presence of
su16f (5µM) for another 14 days. Shown are representative images on day 21.
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Figure 2.19. ERK1/2 and PI3K pathway is involved in PDGF-BB-mediated effects of PDCs.
(A). PDCs were pretreated with ERK1/2 inhibitor U0126 (10µM) for 1 hour, followed by growth factors
for 30 mins. pSmad+ cells were detected by immunofluorescence and counterstained with DAPI.
Magnified images showing positive or negative pSmad staining in nucleus of single cell. Representative
images from three independent experiments are shown.
(B). Quantification of pSmad positive cells.
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(C). Effect of U0126 on ERK1/2 signaling: PDCs were pretreated with U0126 (10µM) for 1 hour,
followed by PDGF-BB for 30 mins. Total cell lysates were immunoblotted using indicated antibodies.
(D). PDCs were pretreated with PI3K inhibitor LY294002 (10µM) for 1 hour, followed by the treatment
with growth factors for 30mins. pSmad+ cells were detected by immunofluorescence and quantified.
(E). Effect of LY294002 on AKT signaling: PDCs were pretreated with LY294002 (10µM) for 1 hour,
followed by PDGF-BB for 30 mins. Total cell lysates were immunoblotted using indicated antibodies.
LY=LY294002. Values are mean ± SD, ** p<0.01 vs control, #p<0.01.

Here we propose a mechanism underlying the effects of PDGF/PDGFRb signaling in PDCs
(Figure 2.20). In response to the injury, there is an increase in the expression of PDGFRβ or expansion of
cells expressing PDGFRβ. The binding of PDGF to PDGFRβ activates ERK1/2 MAPK and PI3K/AKT
signaling in PDCs thereby promoting cell proliferation, migration and inhibiting apoptosis. However,
during osteogenesis, PDGF-BB downstream signaling reduces the canonical BMP2/Smad pathway and
target gene expression, suppressing cell differentiation while maintaining their proliferative potential.
This effect is mediated at least via both ERK1/2 MAPK and PI3K/AKT signaling pathways. Further
studies are required to understand how these interactions play out in vivo.
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Figure 2.20. Schematic diagram of proposed mechanism of PDGF effects in periosteum
derived cells and its interaction with BMP2/Smad signaling.
The binding of PDGF with its receptors, mainly through PDGFRb, activate multiple
signaling (including ERK1/2 MAPK and PI3K/Akt pathways) in PDCs. It promotes the
proliferation and migration while prevents the apoptosis of PDCs. During osteogenic
differentiation, however, PDGF signaling blocks the canonical BMP2/Smad pathway,
inhibiting the target gene expression thus osteogenesis of PDCs. This effect is mediated at
least via both ERK1/2 MAPK and PI3K/AKT signaling pathways.
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Table 2.1: Antibodies used for flow cytometry.
Epitope
CD45
Ter119
CD31
CD140a
Isotype

Conjugate
eFluor 450
eFluor 450
eFluor 450
APC
APC

Manufacturer
eBioscience
eBioscience
eBioscience
eBioscience
eBioscience

Clone
30-F11
TER-119
390
APA5
eBR2a

Dilution
1:400
1:200
1:400
1:100
1:100

CD140b
Isotype
Sca-1
CD105
CD51
CD90.2
Streptavidin
Streptavidin

Biotin
Biotin
FITC
APC
Biotin
FITC
APC eFluor 780
PE

eBioscience
eBioscience
eBioscience
eBioscience
Biolegend
eBioscience
eBioscience
eBioscience

APB5
eBR2a
D7
MJ7/18
RMV-7
30-H12
47-4317
12-4317

1:100
1:100
1:200
1:200
1:100
1:200
1:400
1:400
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Table 2.2: Growth factors and inhibitors used for cell culture.
Proteins
Recombinant Rat
PDGF-BB
Recombinant
Human BMP-2
su16f
U-0126
LY 294002

Concentration used in culture

Manufacturer

1ng/ml, 10ng/ml

R&D Systems

100ng/ml

PeproTech

5µM
10µM

Torcris Bioscience
Enzo Life Sciences

10µM

Enzo Life Sciences
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Table 2.3: Primers used for real time PCR.
Gene
Dlx5
Noggin
Id1
Bmpr1a
Bmpr2
Bmp2
Gapdh

Forward (5’-3’)
GCCCCTACCACCAGTACG
CACTATCTACACATCCGCCCAG
CTCTACGACATGAACGGCTGT
GGTTCAGCGAACTATTGCCAAA
TACAACACCACTCAGTCCGC
TGGAAGTGGCCCATTTAGAG
AGGTCGGTGTGAACGGATTTG

Taqman Primers
Gene
Gapdh
Bone sialoprotein
Osteocalcin
Alp

Assay reference
Mm99999915_g1
Mm00492555_m1
Mm03413826_mH
Mm01187117_m1
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Reverse (5’-3’)
TCACCATCCTCACCTCTGG
AGCGTCTCGTTCAGATCCTTCT
TGCTCACCTTGCGGTTCT G
TCACCACGCCATTTACCCA
CCTGTCTCCTGTCAACATTCTG
TGACGCTTTTCTCGTTTGTG
TGTAGACCATGTAGTTGAGGTCA

Table 2.4: Antibodies used for western blots.

Antibody
Source
PhosphoRabbit
p44/42MAPK(ERK1/2) (poly-IgG)
Rabbit
p44/42MAPK(ERK1/2)
(poly-IgG)
Phospho-AKT
Rabbit
(Ser473)
(poly-IgG)
Mouse
AKT(pan) (40D4)
(Mono-IgG)
PhosphoRabbit
Smad1/Smad5/ Smad9
(Mono-IgG)
(D5B10)
Rabbit
Smad1 (D59D7)
(Mono-IgG)
Phospho-Tyrosine(pMouse
Try-100)
(Mono-IgG)
Rabbit
PDGFRb
(mono-IgG)
Rabbit
GAPDH
(poly-IgG)

Dilution
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
1:1000
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Company
Cell
signaling
Cell
signaling
Cell
signaling
Cell
signaling
Cell
signaling
Cell
signaling
Cell
signaling
Thermo
Scientific
Santa Cruz

Catalog#
9101
9102
9271
2920
13820
6944
9411
MA515143
Sc-25778

2.4 Discussion
Key findings in this chapter:
•

Expression of PDGFRb in the periosteum increases during fracture healing

•

PDGF-BB promotes the proliferation, migration and prevents apoptosis of PDCs

•

PDGFRb signaling negatively regulates periosteal osteogenesis and blocks BMP2Smad pathway

•

MAPK and PI3K/Akt pathway are involved in PDGFRb mediated inhibitory
effects on periosteal differentiation
It is well established that upon injury periosteal reaction is essential for bone regeneration.

Characteristics and cellular behavior of PDCs have not been well defined. While the role of Wnt/bcatenin, TGF-b /BMP and Indian hedgehog-PTHrP, in osteogenic differentiation of periosteal cells have
been studied, the synergy or opposing effects on differentiation of progenitors is not understood(32,138,139).
In addition, the response of periosteal cells to PDGF, which is released by platelets and serves as the
primary initiating signal for cellular ingress during fracture, has never been studied. In this chapter, we
demonstrate that PDGF signaling is an important negative regulator of osteogenesis in periosteum derived
cells in vitro.

BMSC vs PDCs
Skeletal stem cell (SSC) is a very heterogeneous population and there is still a lack of a unique
marker to define SSC. While most research on SSC concentrated on BMSCs, increasing evidences reveal
the periosteum as a major source of progenitors. To isolate periosteum derived cells from the bone, the
method of mechanical scraping followed by enzymatic digestion(1) is usually used like what we performed
in this study. Experiences from our lab indicate that hypoxia condition (5% oxygen) in the first few days
of growth favors the enrichment of cell colonies, presumably mimicking the in vivo situation(4).
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An

alternative method involves explant culture of the bone with marrow flushed out and free of
muscle/tendon. PDCs will then migrate out of the explant within 3 days(140).
Regardless of differences in isolation method, obtained periosteal cells share common features
between studies including ours. Although a high percentage of cells expressing mesenchymal progenitor
markers (Figure 2.7), PDCs culture is heterogeneous containing pre-osteoblast or osteoblasts(24).
However, in the absence of a specific marker to define MSCs, there seem to have no better option to
allow their isolation from periosteum tissues without cell sorting.
A comprehensive study was recently reported by Colnot group(140) in which BMSCs were
compared with PDCs. Using the renal capsule transplantation approach in Prx1-Cre mouse model, they
demonstrated that BMSCs and PDCs are derived from a common embryonic mesenchymal lineage.
Consistent with other studies(26,27), PDCs share similar expression of cell surface markers that previously
shown to define BMSCs. In addition, PDCs can differentiate into multiple lineages with enhanced
potential on chondrogenesis comparing with BMSCs. Microarray analysis of PDCs and BMSCs indicate
they have distinct molecular profiles. While BMSCs are more enriched in genes related to “bone
turnover” and “immune and hematopoietic lineage” etc, PDCs are more responsive to bone injury.
Several extracellular matrix (ECM) proteins are also highlighted which are upregulated in periosteum
upon injury including Periostin(141). Overall, understanding periosteal biology is important given their
specific potential during bone regeneration process.

PDGFRa vs b
Prior to the injury, we observed expression of PDGFRβ in the intact periosteum. The frequency
of PDGFRβ+ cells doubles after fracture in the early periosteum-derived callus, implicating a major role
this pathway might play in the healing process. The importance of PDGFRβ signaling in periosteal
progenitor cells is also supported by their colony forming potential in vitro. Regardless of PDGFRα
expression, PDGFRβ- cells are not able to form CFU colonies or differentiate into osteoblasts. Population
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of osteoprogenitors are enriched in PDGFRβ expressing periosteal cells. Although PDGFRα has been
reported as one of the markers for mesenchymal stem cells(125), only PDGFRα+ PDCs cannot form CFU-F
colonies. With our current knowledge, multiple markers are required to define MSC.
In PDCs, the mRNA expression of PDGFRα is very low comparing with PDGFRβ as detected by
RT-PCR (data not shown). At the protein level, the abundance of PDGFRα is also lower and the majority
of PDGFRα+ cells co-express PDGFRβ. This expression pattern is retained in vitro suggesting that
PDGFRβ is main path for PDGF signaling in PDCs. Consistent with our findings, in bone marrow
stromal cells, Tokunaga et al.(62) showed that PDGF-AA which acts via PDGFRα had no effect on
osteogenic differentiation. Upon deletion of PDGFRβ gene in MSCs, the inhibitory effect of PDGF-BB
on differentiation was abolished, even though PDGFRα expression was increased in PDGFRβdel/del cells.
PDGFRα and β are not expressed at the same time and locations during development, and the phenotypes
of the knockout mice are also different(45,46) suggesting that the expression of these receptors is regulated
by different mechanisms. Different observation also in BMSCs however, demonstrated that (61) PDGF-AA
promotes osteogenic differentiation. This was observed with similar dose of PDGF-AA, except in
passaged BMSCs over a longer period of time. The reason why conflicting effect was discovered under
the similar condition is unknown. Nevertheless, based on our detection of receptor expression on
periosteum, as well as the ability of isolated cell populations to form MSC like colonies, we concluded
that PDGFRβ signaling plays a predominant role in periosteal cells.

Proliferation and differentiation
In a conditional knock-in mouse model, Olson and Soriano(142) found that increased PDGFRβ
signaling drives cell proliferation and opposes differentiation of vascular smooth muscle and pericytes,
maintaining progenitor potential in vivo. Depletion of PDGFRβ in mesenchymal stromal cells also
decreased the proliferation and migration response while promoting osteogenic differentiation.(62) As
expected, we observed that PDGF promotes the proliferation and migration of PDCs in accordance to
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previous studies on other mesenchymal cell types. Osteogenesis was however inhibited in the presence of
PDGF-BB. The growth factor effect seems to be temporary, as withdrawing PDGF could abolished its
inhibitory effect. In addition, PDGF-BB potently inhibits BMP2-induced osteogenesis of PDCs despite its
mitogenic potential. These observations led to our central hypothesis that PDGF-BB inhibits periosteal
differentiation through modulating BMP2 signaling.
Dosing and timing is an important factor affecting osteogenic differentiation in vitro. In the
present study, we observed a dose-dependent effect of PDGF-BB on the proliferation and differentiation
of PDCs. We chose the dose of 10 ng/ml PDGF due to its prominent effects on PDCs. While the
concurrent combination of PDGF and BMP2 inhibit osteogenesis, the sequential combination of treatment
did not affect BMP2-induced osteogenesis. Since we are particularly interested in exploring the
mechanism underlying the inhibitory effect of PDGF, especially the crosstalk between two pathways, we
did not further explore the possibilities with different other combinations. It is possible that particular
treatment regimen could further enhance periosteal differentiation.

BMP2 signaling and PDGF
BMP2 expression in periosteum is induced immediately after injury and sustained during
inflammatory phase(143,144). BMP2 signaling (pSmad1/5/8) was also detected in periosteal callus by
immunostaining as early as 72 hours post fracture(144). In the current in vitro study, we provide the first
evidence that PDGF-BB inhibited canonical BMP2-Smad signaling in PDCs, as well as the expression of
BMP2 target genes. This effect was specifically attributable to PDGFRb, since PDGFRb inhibition
rescued the effects of PDGF on signaling and osteogenesis.
We did not observe activation of Smad signaling by PDGF-BB in PDCs, although there was a
study showing that Smad1/5/8 signaling in BMSCs was activated after 1-hour treatment of PDGF-AA(61).
In addition, we examined the endogenous BMP2 and receptors expression in PDCs. Both types of
receptors are strongly induced in the periosteum in the early stage of fracture repair(90-92). The mRNA
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expression level of Bmpr1a, Bmpr2 and Bmp2 was not affected by PDGF-BB at any of the time point
examined. BMP2 has been reported to activate non-canonical pathways including ERK1/2 and p38
MAPKs in osteogenic cells and cell lines(145-147). In periosteum derived cells, we did not detect activation
of a non-canonical MAPK pathway in response to BMP2, and our data suggest inhibitory effects of ERK
MAPK on Smad signaling. The contribution of PDGFRb inhibitor also suggests the major role of
PDGFRb signaling. However, despite the use of a low concentration of selective biochemical inhibitor to
target PDGFRb, we cannot rule out its effect on other RTK receptors.

PDGF effects in vitro
In vitro culture system mimics in vivo bone formation process, which include the proliferation of
progenitor cells, followed by differentiation into osteoblasts that secrete extracellular proteins such as
type I collagen; after mineralization of the matrix, they undergo apoptosis or further differentiate into
osteocytes(131). Using the in vitro culture system, we demonstrated here that PDCs are targets for PDGFBB, which contributes to cell proliferation, migration and survival. Our results characterized the
inhibitory effects of PDGF-BB on osteogenic differentiation and explored the possible mechanisms. We
also studied the influence of PDGFR inhibitors on periosteal differentiation which has significant positive
impact.
In the context of bone healing in vivo, the final regenerative outcome is dependent on progenitor
proliferation and migration, as well as osteogenic differentiation. Thus even PDGF signaling is
antagonistic to osteogenic differentiation, an increase in progenitor proliferation and migration may
enhance bone healing overall. Considering the stepwise nature of bone repair, BMP2 and PDGF may play
distinct role at different stages of fracture healing. Periosteal progenitor cell recruitment and proliferation,
promoted by PDGF, could be essential for the following osteogenic differentiation induced by BMP2. In
vivo study is needed to understand the role of PDGF-BB/PDGFRb signaling in periosteum-mediated bone
regeneration.
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Chapter 3: Role of PDGF-BB/PDGFR-b signaling on
periosteum mediated bone regeneration in vivo
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Chapter 3
3.1 Introduction
Our understanding of gene function in bone regeneration in vivo has largely expanded by the
development of transgenic mouse models(148,149). Among which, the Cre/loxP recombination system has
emerged as a powerful tool in genetic manipulations(150). Cre recombinase is a 38 kDa protein from
bacteriophage P1 which recongizes site specific recombination between two loxP sites. Depending on the
orientation of loxP sites, two in the same orientation results in the excision of the intervening DNA upon
Cre recombination, after which only one loxP site remains. This could be achieved by crossing Cre
recombinase transgenic mice, in which Cre is expressed under the control of a promoter that is active in
specific cell types, with the floxed mice in which gene of interest is floxed. When Cre recombinase gene
is fused with a modified estrogen receptor ligand binding domain (ERT2), it further allows the
temoporally controlled activation of Cre expression by tamoxifen delivery.
Multiple lines of evidence have suggested the presence of a perivascular niche for mesenchymal
stem cells in both mouse and human tissue(151). Perivascular cells are believed to provide the source of
osteoprogenitors for bone remodeling(152,153). Alpha-smooth muscle actin (aSMA) is the actin isoform that
predominates within vascular smooth-muscle cells. It is a marker for pericytes/myofibroblasts, which has
been used to identify mesenchymal progenitor cells in vitro (154). Previous lineage tracing studies from the
Kalajzic lab have demonstrated the contribution of aSMACreERT2 expressing mesenchymal progenitor
cells during fracture healing (33,34).
In this chapter, we aimed to evaluate the effects of PDGF/PDGFRβ signaling on the fracture
healing in vivo. We generated a transgenic mouse model to conditionally delete PDGFRb in aSMA
labeled progenitor cells and examined the effects of deleting PDGFRb signaling during fracture healing.
Based on the findings we discovered in chapter 2, we hypothesize that deleting PDGFRb in PDCs will
impact fracture healing and potentially enhance bone formation in vivo.
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3.2 Study Design
The generation of experimental mice will be described in the Material and Methods. The
breeding strategy is demonstrated in Figure 3.1A. 8-10 week old female mice were used for fracture
studies. Cre negative Pdgfrbfl/fl littermates were used as controls.
Femur fractures were performed for the evaluation of bone healing. Tamoxifen was delivered on
the day of and two days after fracture to conditionally delete PDGFRb in aSMACreERT2 expressing
cells. Previous studies with this model have demonstrated that a primary cartilaginous callus forms by day
7, followed by a bony callus on day 14, which remodels by day 21. Histology and µCT analysis was
performed at indicated time point as shown in Figure 3.1B.
Animals were excluded from the study if they met the following criteria: pin obviously bent on
X-ray or no longer correctly positioned in medullary canal, multiple fracture occurred, or fractured at
upper/lower 1/3 of femur. 8-11 mice per group were analyzed based on the estimation of 20% variation
and our expectation of differences to be 30% between the groups (effect size= 30% difference ÷ 20%
variation = 1.5, a=0.05, b=0.1, statistic power=90%).

Figure 3.1. Study design for the major experiments in Chapter 3.
(A). The breeding strategy: a two-step breeding procedure was used to generate experimental mice.
(B). Experimental design: femur fractures were performed on 8-10 week old female mice.
Tamoxifen was administrated on day 0 and day 2 after fracture. X-Ray was taken once a week for
three weeks to observe pin fixation and monitor callus formation during fracture healing processes.
Mice were sacrificed at indicated time point to perform histology and µCT analysis.
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3.3 Materials and Methods
Mouse strains and fractures
All animal procedures were approved by the institutional animal care and use committee at UConn
Health. The aSMACreERT2 mice were generated as previously described(33). Ai9 reporter mice (B6;
129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J) were obtained from Jackson Laboratory (Bar Harbor, ME,
USA). aSMACreERT2 mice were bred with Ai9 to generate SMACre/Ai9 mice (termed SMA9) as
described before(34). Pdgfrbflox/flox mice were obtained from the Laboratory of Dr. Soriano. To generate
aSMACreERT2-Pdgfrbfl/fl mice, hemizygous aSMACreERT2 transgenic mice were crossed with
Pdgfrbfl/fl mice to produce heterozygous Pdgfrbfl/+ offspring carrying a Cre allele. These mice were then
crossed with Pdgfrbfl/fl mice generating four genotypes: aSMACre+-Pdgfrbfl/+; aSMACre+-Pdgfrbfl/fl;
aSMACre--Pdgfrbfl/fl ; aSMACre--Pdgfrbfl/+. aSMACre+-Pdgfrbfl/fl mice were then crossed with Pdgfrbfl/fl
mice to generate experimental mice: aSMACreER+-Pdgfrbfl/fl or aSMACreER--Pdgfrbfl/fl.(Figure 3.1)
Genotyping for Pdgfrb flox and Cre was performed with the PCR primers shown in Table 3.1. Detection
of Cre-induced recombination was carried out using specific primers (Table 3.1).
In order to conditionally delete PDGFRb in aSMACreERT2 expressing cells, tamoxifen (Sigma
Aldrich, St.Louis,MO) dissolved in corn oil was administrated at the dose of 75µg/g of bodyweight by
intraperitoneal injection, on day 0 and day 2 post fracture. Closed transverse femoral fractures were
generated as described in Chapter 2.

Radiographic images
To observe pin fixation and monitor callus formation during fracture healing, fractures were radiographed
using a Faxitron Cabinet X-Ray system (Faxitron X-Ray Corporation, Lincolnshire, IL) at the setting of
26kV for 3 seconds under anesthesia on day 0, 7, 14 and 21 post fractures. Volumetric analyses were
conducted at the MicroCT Imaging Facility at the University of Connecticut Health Center using cone
beam micro-focus X-ray computed tomography (µCT40, Scanco Medical, Bassersdorf, Switzerland), at a
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resolution of voxel size 12 µm, energy 55 kV and intensity of 145 µA. Densitometric analysis of fractured
bone were done from the center of the fracture hundred serial slices up and down countering every 10th
slide and interpolating in between. Bone density, bone mass and callus volume were determined and
presented as mean ± SD.

Histology
Femurs were fixed in 10% formalin (Sigma) for 5 days at 4ºC. The intramedullary pins were then
removed and bone were incubated overnight in 30% sucrose/PBS, and embedded in Cryomatrix (Thermo
Fisher Scientific, Waltham, MA, USA). 7µm sections were obtained on a Leica crystat (Wetzler,
Germany) using a tape transfer system (Section-lab, Hiroshima, Japan). Sections were stained with 0.02%
Fast green followed by 0.1% Safranin O, then stained with Mayer’s Hematoxylin (Sigma-Aldrich). For
Von Kossa staining, sections were incubated with 5% silver nitrate solution and developed under UV
Crosslinker (Stratalinker) on auto-crosslink for 2 cycles. After rinsing with distilled water, sections were
counterstained with Hematoxylin. After histological staining, sections were coverslipped in 50%
glycerol/PBS and imaging was performed using a Zeiss Oberver Z.1 inverted microscope.

EdU labeling in vivo
Cell proliferation in vivo was measured by EdU assay. To capture cells during early proliferative phase,
EdU dissolved in normal saline was administrated at the dose of 3µg/g of bodyweight by intraperitoneal
injection on day 2 and 3 post fracture and mice were sacrificed on day 4. Frozen sections of fractured
femurs were stained with the Click-It EdU Alexa Fluor 647 cell proliferation assay kit (Invitrogen,
ThermoFisher) as per manufacturer’s instruction. After staining, sections were coverslipped in 50%
glycerol containing DAPI (1:5000) and imaging was performed using a Zeiss Oberver Z.1 inverted
microscope.
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Image analysis and quantification
Images were analyzed using Fiji image analysis software (NIH). Briefly, regions of interest (ROI) were
drawn on each image and RGB images were split into single color channel 8-bit images.
For EdU assay analysis: same size of the periosteal region proximal to fracture site was chosen as ROI.
For histological analysis of fracture healing: callus area was manually drew as ROI based on the
histomorphology of fractures.
For Safranin O: The threshold was set for the blue channel 8-bit image, which has the least background
and best contrast for Safranin O. Callus area and cartilage area fraction (%) was measured.
For Von Kossa: The threshold was set for the red channel 8-bit image, which has the least background
and best contrast for Von Kossa. Callus area and mineralized area fraction (%) was measured.

Statistical Analysis
Results were analyzed using unpaired student’s t-test for comparison between two groups using GraphPad
Prism. Data are presented as mean ± SD. p-values < 0.05 were considered statistically significant.
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3.4 Results
3.4.1 PDGFRb is expressed on the aSMA labeled periosteum progenitor cells during
fracture
Our lab has previously generated aSMACreERT2 transgenic mice by a combinatorial Cre/loxP
system which harbors a Cre recombinase under the control of the promoter of aSMA(33). The Cre
recombinase gene was fused with a modified estrogen receptor ligand binding domain (ERT2), which
allows the temoporally controlled activation of Cre expression by tamoxifen delivery. When crossed with
Ai9 reporter mice, Cre recombination driven by aSMA promoter can be detected by red fluorescence
(TdTomato). aSMACreERT2/Ai9 mice thus provide a powerful tool to trace progenitor cells and their
progeny, enabling us to further study signaling pathways that regulate aSMA labeled progenitors.
To investigate the potential role of PDGFRb signaling in vivo, we created tibia fractures in the
aSMACreERT2/Ai9 mice (Figure 3.2). Tamoxifen was administrated the day before and on the day of
fracture in order to label aSMA expressing periosteal cells. We first examined the population of aSMA+
periosteal cells during early stage of fracture by flow cytometry. Unfractured periosteum and callus
periosteum from day 4 and day 10 fractures were collected for analysis. The aSMA+ TdTomato
expressing cells were determined on CD45/Ter119/CD31- population, and Cre+ mice without Tamoxifen
treatment were used as control to set up gating. As shown in Figure 3.2, there was a significant increase
of aSMA+ periosteal progenitor cells during fracture from only around 3% within non-hematopoeitic
lineage on unfractured periosteum, to 18%±3% on day 4 and 35%±4.5% on day10.
Further analysis of PDGFR expression on aSMA+ periosteal progenitor cells demonstrated a
similar pattern with total CD45- population as shown in Figure 2.4B. There was very few PDGFRa+ only
population and most PDGFRa+ cells co-express with PDGFRb. Comparing with total nonhematopoietic
population, there seem to be more PDGFRb+ cells within aSMA+ population, althought there was no
significant change of PDGFR expression during fracture. ( Figure 3.2 E)
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Figure 3.2. Flow cytometry analysis of aSMA expressing periosteal cells during fracture.
(A).Experimental design: tibia fracture was created on 8-10 week old aSMAERT2/Ai9 mice.
Tamoxifen was given the day before and day of fracture to label aSMA-expressing cells. Unfractured
periosteum were collected on day 0 and fractured samples were collected 4 and 10 days after fracture.
TMX= Tamoxifen.
(B).Representative dot plot of flow analysis on day 10 is shown. The frequency of aSMA+ tdTomato
-

expressing cells was determined within the nonhematopoietic population (CD45/Ter119/CD31 ).
(C).Quantification of aSMA cell frequency at different time points following fracture. Both tibias
from two mice were pooled for each sample, n=3 samples for each group.
(D).PDGFRs expression on aSMA+ cells was analyzed by gating on tdTomato+ population.
Representative dot plot of flow analysis on day 10 is shown. (E). Quantification of PDGFRs
expression on aSMA+ cells at each time point during fracture. Values are mean ± SD, * p<0.05 vs
control, *** p<0.001 vs control.
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3.4.2 PDGF-BB promotes the proliferation and migration of aSMA+ PDCs
The expression of PDGFRs on aSMA+ periosteal cells motivates us to further study their
response to PDGF. We treated aSMACreERT2/Ai9 mice with tamoxifen for 2 days before isolating
periosteal progenitor cells. On day 4 ex vivo, there were some cells labeled with tdTomato as shown in
Figure 3.3A. To evaluate the effects of PDGF-BB on aSMA expressing periosteal progenitor cells, we
gated on tdTomato+ population and analyzed the percentage of EdU+ cells within aSMA+ population by
flow cytometry. As expected, comparing with control, there was significant higher percentage of EdU+
aSMA+ cells upon PDGF-BB treatment (Figure 3.3B).

Figure 3.3. PDGF-BB promotes
the proliferation of aSMA
expressing PDCs.
(A).aSMACreERT2/Ai9 mice were
injected
with
tamoxifen
for
consecutive two days before sacrificed
for the isolation of PDCs. Shown is the
representative image of aSMA+
tdTomato expressing PDCs on day 4.
(B). Passaged PDCs were serum
starved overnight and treated in the
presence or absence of 10 ng/ml
PDGF-BB for 20 hours. Cells were
then incubated with EdU for 4 hours
and proliferating cells within aSMA+
population were analyzed by flow
cytometry.
*** p<0.001 vs control.
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The migration of aSMA+ cells was also evaluated by scratch assay. PDGF-BB exhibited
significant chemotactic effects on aSMA+ cells as measured by wound healing speed (Figure 3.4). While
cells treated with PDGF-BB already healed after 48 hours, the wound in control group was still left open.
Taken together, these data demonstrated the effects of PDGF-BB on aSMA labeled periosteal progenitor
cells.

Figure 3.4. PDGF-BB promotes the migration of aSMA expressing PDCs.
(A). Experimental design: aSMACreERT2/Ai9 mice were injected with Tamoxifen for consecutive two
days before sacrificed for the isolation of PDCs. Confluent monolayer PDCs were serum starved
overnight and then scratched to create a wound in culture. Cells were then treated with or without
10ng/ml PDGF-BB and followed for 48 hours. Images were taken after 18, 30 and 48 hours.
Representative images of cell migration is shown. Lines indicate frontier area of migrated cells.
(B). Quantification of cell migration after 30 hours. Wound closure (%) was represented as migrated
wound distance divided by original distance. *** p<0.001 vs control.
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3.4.3 Generation of conditional PDGFRb knockout mouse model
Transgenic mice provide powerful tools to understand gene function in a physiological
environment, since in vitro studies cannot fully recapitulate what might be happening in vivo. However,
our current understanding of PDGFRb signaling is limited by the lethal effects of global deletion of
PDGF receptor(46,155). As shown by Soriano et al(46), PDGFRb mutant mice died perinatally, exhibiting
defects in kidney glomeruli due to a lack of mesangial cells and disorders in blood. Given the high
expression of PDGFRs and significant response of aSMA labeled periosteal cells to PDGF-BB, we
created a conditional knockout mouse model by crossing aSMACreERT2 mice with Pdgfrbflox/flox.
PDGFR beta protein is composed of an extracellular ligand binding domain containing five
immunoglobulin-like loops, a transmembrane domain, and an intracellular domain harboring two protein
kinase domains(156). PDGFR beta floxed mice was previously generated by Dr. Soriano as described
before(157). Briefly, the targeting vector introduced two LoxP sites flanking exons that encoding the first
two immunoglobulin domains(157) (Figure 3.5). When crossed with aSMACreERT2 mice, conditional
knockout PDGFRb in aSMACre expressing cells can be achieved by tamoxifen delivery. Thus, our
mouse model enables the temporal and spatial deletion of PDGFRb to study its role in vivo.
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Figure 3.5. Schematic diagram of the conditional allele of Pdgfrb.
The 39.91 kb PDGFRb genomic locus is composed of 23 exons as indicated by blue boxes. The protein
coding area results in the production of PDGFRb. The PDGFRb protein structure includes 5
immunoglobulin-like domains + transmembrane domain+ 2 protein kinase domains. The targeting vector,
introduced 2 loxP sites (red arrowheads) at ~500 base pairs (bp) upstream of and 2,100 bp downstream
from the exon 3-7 which encode the 1st and 2nd immunoglobulin domain. Blue arrowheads indicate FRT
sites flanking a PGK-neo cassette. DTA is a PGK-DTA cassette used for negative selection in ES cells.
Adapted from (Schmahl, et al 2008) (157)

80

Cre-mediated recombination was confirmed by PCR in DNA from fracture callus (Figure 3.6A).
A 389 bp deleted band was detected in Cre+ mice. We also checked the efficiency of Cre recombination
by flow cytometry. Comparing with Cre- mice, there was a significant decrease of PDGFRb expression of
in Cre+ mice from about 40% to 15% in non-hematopoietic/endothelial cells, as shown in Figure 3.6B.

Figure 3.6. Generation of aSMACreERT2-Pdgfrbfl/fl mice.
(A). Validation of Cre-induced recombination by PCR. Genomic DNA was extracted from fracture
callus 10 days post tibial fracture. A 389 bp deleted band was detected in Cre+ mice. Samples were
from individual mice.
(B). Periosteum derived callus were collected from Cre+ and Cre- mice after 10 days post fracture.
Tamoxifen was delivered on day 0 and day2. Expression of PDGFRs were analyzed by flow
cytometry as described previously (gated on CD45/Ter119/CD31- population). A representative plot
was shown.
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3.4.4 Deleting PDGFRb enhances osteogenesis of PDCs in vitro
To compare the osteogenic potential of PDCs with or without the deletion of PDGFb, we
performed in vitro differentiation assays. Primary PDCs were treated with 4-hydroxytamoxifen on day 4
and day 6 when cells were attached and colonies formed, and then induced to osteogenic differentiation
with b-glycerophosphate and ascorbic acid from day 7 to day 21. To evaluate the effects on osteogenic
differentiation, ALP and Von Kossa staining were performed. As shown in Figure 3.7, Cre+ cells showed
more intense ALP and increased Von Kossa staining compared with Cre- cells, suggesting that deleting
PDGFRb in aSMACre+ PDCs enhances osteogenesis in vitro. We also examined in BMSCs which
exhibited a similar effect.

3.4.5 Deleting PDGFRb impairs proliferation of periosteal cells following fracture in vivo
An essential step for fracture repair is the proliferation of progenitor cells during early stage after
injury(128). Given the mitogenic effect of PDGFRb signaling, we wondered whether deleting
PDGFRb would affect periosteal proliferation in vivo. Tamoxifen was delivered on the day and two days
after fracture to activate Cre-mediated deletion of PDGFRb (Figure 3.8). EdU was injected to label
proliferating cells 24 and 48 hours prior to sacrificing the mice on day 4.
We focused on the thickened periosteum area proximal to the fracture site and quantified the
percentage of EdU+ cells. As shown in Figure 3.8, while around 20% proliferative cells were observed in
Cre- mice at day 4 post fracture, there was a significant decrease in the number of EdU+ cells in Cre+
group. This suggests impaired proliferative capacity of periosteal cells when PDGFRb signaling is
perturbed in aSMA expressing cells.
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Figure 3.7. Enhanced osteogenesis in PDGFRb deleted PDCs in vitro.
(A). Experimental design: Primary periosteal derived cells were isolated from
aSMACreERT2Pdgfrbfl/fl mice and treated with 4-hydroxytamoxifen (4-OH TMX) on day 4 and day
6. Cells were induced to osteogenic differentiation from day 7 until day21. (B). ALP and Von
Kossa staining of PDCs on day 14 and day 21. (C). Quantification of ALP positive staining.
(D). Quantification of Von Kossa staining.
* p<0.05, *** p<0.001 vs Cre- control.
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Figure 3.8. Deleting PDGFRb impairs proliferation of periosteum derived cells in vivo.
(A). Experimental design: Femur fracture was performed on 8-10 week old female
aSMACreERT2Pdgfrbfl/fl mice. Tamoxifen was delivered on the day of and two days after the fracture to
delete PDGFRb. EdU was injected on day 2 and day 3 and mice were sacrificed on day 4.
(B). Representative images of EdU staining on day 4. Frozen section of fractured femur was stained with
EdU (Yellow: Alexa Fluor 647) and DAPI (blue). Dashed lines indicate fracture site. Periosteal area
proximal to fracture site was chosen to quantify EdU+ cells on the periosteum.
(C). Quantification of the percentage of EdU+ cells. Same periosteum area was analyzed in each mouse.
*** p<0.001 vs Cre- control, N=6 mice in each group.
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3.4.6 Effects of conditionally deleting PDGFRb on fracture healing in vivo
To assess whether deleting PDGFRb would influence fracture healing in vivo, we examined the
effects on fracture healing over the course of 21 days. We utilized a standard closed fracture model which
involves the insertion of an intramedullary pin into the femur, followed by the induction of a transverse
fracture by a dropped weight from a blunt guillotine. This results in a transverse fracture with minimal
(158)

damage to soft tissue. Pin removal is easily accomplished after removing the growth plate

.

As shown by radiographic evaluation, the repair process followed the traditional phases/steps in
both groups with a callus formation (radiolucent on X-ray) on day 7 which mineralized by day 14. Bone
remodeling occurred at later stage with the resorbed callus seen on X-ray by day 21 (Figure 3.9). We did
not observe obvious differences from radiographic images between Cre+ and Cre- mice.
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Figure 3.9. Radiograph images of fracture healing process in aSMACreERT2-Pdgfrbfl/fl mice.
(A). Experimental design: 8-10 week old female aSMACreERT2-Pdgfrbfl/fl mice were performed femur
fracture. Taxmoxifen was administrated the day of and two days after fracture to delete PDGFRb in
aSMACre expressing cells. X-Ray was taken once a week for three weeks to observe pin fixation and
monitor callus formation during fracture healing processes. Mice were sacrificed at indicated time point
to perform histology and µCT analysis. (B). Serial X-ray images of fracture healing process during 21
days.
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Histomorphometric analysis(159) was performed on Safranin-O/Fast green stained calluses at 7
days post fracture (Figure 3.10A-C). While the total callus area was not affected, there was a decrease in
the percentage of cartilage area in Cre+ mice (p=0.05). Less cartilage was formed when PDGFRb was
conditionally deleted.
Further analysis was performed on the Von Kossa stained calluses at 14 days post fracture
(Figure 3.10D-F). Comparing with Cre- group, the callus area was smaller in Cre+ mice. There was a
tendency of increased ratio of mineralized and total callus in PDGFRb conditional knockout mice
(p=0.06). By day 21, MicroCT imaging showed that both total volume and bone mass were comparable
between Cre+ and Cre- mice (Figure 3.11).
Taken together, conditionally deleting of PDGFRb in aSMACre expressing cells in vivo resulted
in a smaller callus on day 14. It also modulates chondrogenic/osteogenic differentiation process with less
cartilage and more mineralized tissue in the newly formed callus. Further mechanical testing is needed to
examine the effects on bone strength at later time points.
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Figure 3.10. Histological analysis of calluses on day 7 and day 14.
(A). Representative images of Safranin O staining on day 7. (B) Quantification of callus area and (C)
cartilage area fraction on day 7 was shown. (D). Representative images of Von Kossa staining on day 7.
(E) Quantification of callus area and (F) mineralized area fraction on day 14 was shown. N=8-10 mice in
each group.
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Figure 3.11. MicroCT analysis of calluses on day 21.
(A). Representative microCT images of calluses on day 21. (B). Representative reconstructive 3D images.
(C) Quantification of total volume and bone mass was shown. N=9-11 mice in each group.
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Table 3.1: Primers used for genotyping and recombination.
Gene
Pdgfrbfl
Cre
Cre
recombination

Forward (5’-3’)
TACCAGGAAGGCTTGGGAAG
CAG GTT CGT TCA CTC ATG GA
GGAAAAGCAGGTTTGTGC
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Reverse (5’-3’)
CCAGTTAGTCCACTTATGTTG
TGC ATG ATC TCC GGT ATT GA
CCAGTTAGTCCACTTATGTTG

3.5 Discussion
Key findings in this chapter:
•

PDGFRb is expressed on aSMA labeled periosteal progenitor cells during fracture

•

PDGF-BB promotes the proliferation and migration of aSMA+ PDCs

•

Deleting PDGFRb in aSMA-Cre expressing cells enhances osteogenesis in vitro

•

Deleting PDGFRb in aSMA-Cre expressing cells impairs cell proliferation in vivo

•

Cartilage area/callus area decreases on day 7 after conditionally deleting PDGFRb

•

There is a smaller callus and increased mineralized area/callus area on day 14 after
conditionally deleting PDGFRb

In this chapter, we carried out an in vivo study to further investigate the role of PDGF/PDGFRb
signaling during fracture repair. Using aSMACreERT2-Pdgfrbfl/fl mice, we attempted to further
understand the contribution of PDGFRb expressing cells to bone formation in vivo. Our major finding is
that deleting PDGFRb in aSMACre labeled cells impairs cell proliferation in vivo but enhances
osteogenesis in vitro. During fracture, there is less percentage of cartilage and more mineralized bone
upon conditionally deleting PDGFRb . Further investigations are needed to evaluate bone strength at later
time points.

Other transgenic mouse model
PDGF receptors and ligands are essential for the development and normal function of many
tissues(160). As demonstrated more than 20 years ago, PDGFRb deficient mice exhibited a defect in kidney
glomeruli and died before birth(46). Thus conditional knockout model is required to avoid lethal effects in
embryos. Genetic studies have uncovered important roles of PDGFRb in the context of many diseases
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such as hypercholesterolaemia and liver injury(161,162), the role of PDGF on bone formation in vivo is
however less investigated. A major effort was made by Tokunaga et al(62), who created a conditional
knockout model by crossing ubiquitous Cre (CAGGCre-ER) mice with PDGFRbflox/flox mice. Tamoxifen
was delivered at 4 week of age by oral administration and mice were found in good health without
abnormalities including skeletal system. Fractures were performed however, after another 4 weeks after
tamoxifen delivery and only histology on day 7 was reported. They demonstrated that at day7 post
fracture, the callus tend to be smaller (although without statistical differences) with increased ratio of
woven bone/callus. The authors interpreted that this maybe due to less cell recruitement and premature
osteogenic differentiation in PDGFRb deleted mice.
This work provides a novel model to understand PDGFRb functions in vivo, however is limited:
1) the deletion of PDGFRb is universal, making it difficult to understand the signaling in specific cell
types such as progenitor cells; 2) the change happened during the 4 weeks period between taxmoxifen
delivery and fracture induction was unknown, comfounding the results observed; 3) Only one time point
was reported, less than enough to evaluate the overall bone regeneration. In the present study, we
attempted to create a conditional knockout model which is more specific to target mesenchymal
progenitor cells within periosteum, and followed the entire course of fracture.

Contribution of aSMACre expressing cells to bone
In vivo analysis of periosteal progenitor cells has been limited by a lack of specific gene
expressed in periosteum. In searching for an appropriate transgenic Cre mouse model, we are particularly
interested in the marker of aSMA. Several lines of evidences(152-154) indicate that cells with a
pericyte/myofibroblast phenotype have the potential to differentiate into osteoblast. Kalajzic group first
described the use of aSMA transgene to identify osteoprogenitor populations in vitro and in vivo(33,154).
The contribution of aSMACre expressing cells to bone regeneration is well demonstrated in the lineage
tracing studies(33,34). Using aSMACreERT2 mice combined with Col2.3GFP reporter, progenitor cells
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were traced during fracture healing process

(33,34)

. Marked expansion of aSMACre+ cells were observed

at periosteal callus, which make the major contribution to bone regeneration. Multiple mesenchymal stem
cell markers are present on aSMA labeled cells including PDGFRb(34), making it a good candidate to
target cells of our interest.

Interpretations of the results
In the present study, we followed the course of fracture healing and performed bone
histomorphometry to examine fracture healing. After 7 days post fracture, the ratio of cartilage area to
total callus area was decreased in PDGFRbdel/del mice (p=0.05, n=8-10). This is consistent with previous
mentioned global knockout mouse model(62). After 14 days, the callus area was smaller and the percentage
of mineralized tissue was higher in PDGFRbdel/del mice (p=0.06, n=8-10). On day 21, microCT analysis
showed similar total volume and bone mass between two groups.
The effects observed in current model might be a result of the bidirectional function of PDGFRb
signaling. As a potent mitogen, the proliferation of mesenchymal cells was inhibited upon conditionally
deletion of PDGFRb in vivo. On the other hand, since PDGFRb negatively regulates osteogenic
differentiation, enhanced osteogenesis of PDCs was observed in vitro. Thus, impaired progenitor cells
proliferation might be compensated by enhanced osteogenesis during fracture healing. It also seems that
deleting PDGFRb favored osteogenesis over chondrogenesis, although total bone mass was comparable
after 21 days. We did not observe differences of callus size on day 7 although there was reduced cell
proliferation on day 4 in Cre+ group. It is possible that other signaling might compensate for the reduced
PDGFRb signaling in the later stage. There was about 10% increase of PDGFRa+ population after
deleting PDGFRb (data not shown), increased PDGFRa+ signaling may contribute to the reduced
PDGFRb signaling.
There are also limitations regarding the transgenic mice and injury model, making the analysis of
the results more complex. First of all, the potency of the transgenic promoter which drives Cre
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recombinase expression is critical to achieve efficient gene recombination(149). The aSMA promoter we
used in the current study has been examined to be broadly expressed in number of tissues including
periosteum, periodontium, as well as the smooth muscle layer of the blood vessels and bladder etc(163).
Although Cre mediated recombination was confirmed in fracture callus by PCR, given the percentage of
aSMA expressing cells during fracture (about 30-40% within mesenchymal lineage), it is still challenging
to quantify the changes caused by a subset of cells. Our current mouse model did not contain a fluorescent
Cre reporter, making the evaluation of PDGFRb signaling difficult.
Secondary, the preliminary study was performed on adult female mice. Many biomedical
research involves studies of males rather than females, based on the idea that females are more variable
due to estrous cycle. However, comparing analysis of gene expression in various tissues actually shows
that male gene expression is slightly more variable than that of females(164). Nevertheless, a
comprehensive study including males and females is needed, since the function of PDGFRb signaling
might be influenced by sex. In addition, the final outcome that determines the fracture healing is
improved or delayed is mechanical strength, thus mechanical testing will further help evaluate the effects.
Thirdly, there were still individual variables of the fractures within each group, although the
radiography images were used to help control the quality. Unlike the critical-sized defect model, the
accurate position and strength in each fracture is different. It might be difficult to detect phenotypical
differences between mice if the effect is subtle.
Nevertheless, to our knowledge, the present study is the first report on conditionally deleting
PDGFRb during bone regeneration. We detected differences in cell proliferation and composition of
callus upon depleting PDGFRb in mesenchymal progenitor cells. Ours and previous study(62) suggest that
PDGFRb plays a role in cell expansion and differentiation, although fracture healing can still proceed in
the reduction of PDGFRb. Despite limitations, it gives an insight of what might actually happen in vivo
and provides a preliminary information for further studies.
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Chapter 4: Major conclusions, Implications and
Future Directions
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Chapter 4
Tremendous progress has been made to understand the molecular regulation of osteogenic
differentiation of bone marrow stromal cells(165). Much is to be learned however about other types of
progenitor cells such as those from the periosteum. PDGF is a potent mitogen and chemotactic for
mesenchymal cells and makes a major contribution to wound healing. To date, the effects of PDGF as
well as the signaling pathways in periosteal derived progenitor cells during bone repair still remain
unclear. This thesis aimed to evaluate the effects of PDGF/PDGFR-β signaling on the periosteal
derived cells in vitro and fracture healing in vivo. Though both the in vitro (Chapter 2) and in vivo
(Chapter 3) approach, we explored the cellular response of PDCs to PDGF as well as the potential
outcome of disrupting PDGFRb signaling during fracture healing.

4.1 Summary of findings
In the present study, we observed expression of PDGFRβ in the intact periosteum. The frequency
of PDGFRβ+ cells doubles after injury in the early periosteum-derived callus, implicating a major role this
pathway might play in the healing process. PDGF-BB promotes the proliferation and migration of PDCs
in vitro, consistent with its effects on other mesenchymal cell types in many studies. In addition, PDGFBB potently inhibits osteogenic differentiation and also BMP2-induced osteogenesis of PDCs. Our data
indicate that PDGF-BB inhibited canonical BMP2-Smad signaling, and the expression of BMP2 target
genes. Use of specific inhibitors indicates that this effect was specifically attributable to PDGFRb and at
least involved ERK/MAPK and PI3K/AKT pathway.
We also created a PDGFRb conditional knock out mouse model and examined the effects of
deleting PDGFRb during fracture healing. In vitro differentiation assay demonstrated that deleting
PDGFRb in aSMA-Cre expressing cells enhances osteogenesis of PDCs. In vivo labeling of proliferative
periosteal cells with EdU presented impaired cell proliferation by depleting PDGFRb in mesenchymal
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progenitor cells. During fracture, there was less cartilage and more mineralized tissue in Cre+ mice.
Further mechanical testing is needed to examine the effects on bone strength.
Taken together, our study supports a potential role of PDGF in sustaining the proliferation and
survival of periosteum derived progenitor cells but inhibiting their osteogenic differentiation. We
demonstrated a novel pathway regulating periosteal differentiation by modulating BMP2-induced
osteogenesis.

4.2 Limitations of the study
While this study points out a critical role of PDGF/PDGFRb signaling in modulating osteogenic
differentiation of the periosteum, there are limitations. Since the majority of our observation are based on
in vitro experiments, the major concern is that in vitro work might not fully recapitulate what might be
happening in vivo. Although we followed up with an in vivo study using conditional knockout model, as
discussed in Chapter 3, it is still difficult to draw a conclusion on the definite role of PDGF/PDGFRb
signaling during fracture based on the preliminary studies. There are drawbacks regarding the transgenic
mice and injury model, and further exploration of in vivo conditions is needed. Besides this, some other
points are needed to take into consideration:
I.

The primary periosteum derived cells might not represent a particularly homogenous
culture of periosteal osteoprogenitors. The mouse periosteum is thin and contains only a few
layers. To our knowledge, researchers have not been able to separate two layers in which only
the inner layer contains progenitor cells; mechanical removal of the periosteum may also result
in contamination of osteoblasts. We have used Col2.3GFP reporter mice in many experiments
and find that reporter expression is very rare in the freshly isolated cells, and is absent in the
early phases of culture. Other cell lineages, including hematopoietic cells, are undoubtedly
present in initial cell preparations, although culture conditions should favor expansion of
mesenchymal progenitor population. Cultured PDCs highly express MSC markers in vitro.
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Nevertheless, primary PDCs (without cell sorting) are a heterogeneous population. However, this
is a drawback of almost all primary cultures.
II.

The chemical inhibitors may not be specific. Although PDGFRb inhibitor (su16f) has been
examined with the most inhibitory activity against PDGFR (IC50=10nM) comparing with
FGFR1, EGFR and VEGFR2(137), PDGFRb knockout data would be more direct and convincing.
In addition, the ERK and PI3K inhibitors have pleiotropic effects in cells. Since they are
common downstream pathways of many mitogens such as fibroblast growth factor 2 (FGF-2)
and epidermal growth factor (EGF) etc, one may expect that other mitogens may also inhibit
BMP2-induced osteogenesis in PDCs. Additional evidence comparing PDGF-BB with other
growth factors would be informative to learn whether the effects we observed are specific to
PDGF in PDCs.

III.

Bone regeneration potential of PDGFRb expressing PDCs is not investigated in vivo.
Previous studies have demonstrated higher proliferative capacity and osteogenic potential of
PDCs comparing with BMSCs(26,140). We made a few attempts at transplanting PDCs into critical
defect mouse model, however the effect was not impressive. Optimization of variables including
cell density, matrix compositions, presence of other cells or growth factors may be needed to
improve efficiency in vivo. A recent study showed that PDCs sorted for CD90 have greater
osteogenic potential in vitro and in vivo(166). Based on our discovery of the essential role of
PDGFRb signaling, it would also be interesting to explore the bone regeneration potential of
PDGFRb expressing PDCs in vivo.
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4.3 Discussion of the findings
Our findings may have clinical implications. Despite the abundant osteogenic effects of BMP2 in
vitro, the effective concentration of rhBMP2 for human use is over ten thousand times higher than that of
cultured cells, and in addition to bone formation, can cause harmful inflammation and bone resorption. It
is possible that other growth factors such as PDGF limit the ability of BMP2 to induce bone formation.
Apart from the role in osteogenesis, PDGF also affects other aspects of fracture healing which will be
discussed below.

PDGF and angiogenesis
Another contribution of PDGF/PDGFRb signaling which is less investigated in this thesis is
neovascularization(167). Vascular endothelial growth factor (VEGF) is a well-known vascular growth
factor during angiogenesis(168). At the vascular injury site, elevated VEGF levels can mobilize bone
marrow derived endothelial progenitor cells into circulation(169), result in vasculogenesis. PDGF can
increase the expression of VEGF during fracture(170). There is study showing that VEGF-A can also bind
to and activate PDGFR expressing cells, inducing VEGFR negative MSCs to migrate and proliferate(171).
During bone formation, Xie at al (172) demonstrated PDGF-BB secreted by preosteoclasts induces
angiogenesis during coupling with osteogenesis. Depletion of PDGF-BB in osteoclast lineage cells using
tartrate-resistant acid phosphatase (TRAP)-Cre: Pdgfbflox/flox mice reduced CD31hi Emcnhi cells numbers
and bone formation. Interestingly, the in vivo effect of PDGF seems to be more prominent in diabetic or
ovariectomized animals (Table 1.2), when the vascular change occurs. Thus, we can expect that the
involvement of PDGF-BB during angiogenesis is also important for fracture healing.

PDGF and osteoclasts
It is well known that osteoblast-osteoclast communication is critical for bone formation(173,174).
While osteoblasts were long known to regulate osteoclast activity and couple with bone resorption,
osteoclasts are also capable of regulating osteoblast performance(175). An early study using different cell
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lines showed that the conditioned medium from osteoclasts cultures contained PDGF-BB which inhibited
BMP4-induced osteogenesis of MC3T3-E1 cells(176). On the other hand, osteoclasts can also control
osteoblast chemotaxis via PDGF-BB/PDGFR-b signaling(177).
To add another layer of complexity, the effect of PDGF-BB on osteoclast was also examined in
vitro and in vivo(178). Exogenous recombinant PDGF-BB enhanced osteoclast precursor cells chemotaxis
and osteoclast formation in cell lines. It also induced osteoclast formation during mandible fracture in
rats. Overall, these data suggest a multifaceted role of PDGF-BB in bone biology.

PDGF and chondrogenesis
The effect of PDGF in cartilage formation is still unclear. There is an in vitro study showing that
PDGF-BB promotes the proliferation of chondrocytes but inhibits endochondral maturation(179). It is safe
and well tolerated by intra-articular injection without gross changes in cartilage appearance or fibrosis(180).
Treatment of cartilage explant cultures with PDGF-AB has little effect on cartilage tissue composition but
decreases tissue tensile integrity(181). In the present study, we did not observe PDGFR expression in the
chondrocytes of periosteal callus on day 10, indicating less involvement in chondrogenic lineage cells.
Nevertheless, since the majority of fractures undergo endochondral osteogenesis, the effect of PDGF on
chondrogenic differentiation of PDCs would also be of interest.

PDGFR inhibitor and bone formation
Imatinib mesylate (IM; GLIVEC) is a gold standard treatement for patients with chronic myeloid
leukemia (CML)(182) and gastrointestinal stromal cells tumors (GISTs)(183). It is a tyrosine kinase inhibitor
against c-abl (including bcr/abl), c-kit and PDGFR, which are actively involved in above disease.
Interestingly, people found that there is a marked increase in biochemical markers of bone formation in
some patients starting imatinib therapy(184). Osteocalcin and procollagen type I N-terminal propeptide
(PINP) increased significantly, while bone resorption markers were stable. This was also associated with
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secondary hyperparathyroidism and these changes return to baseline after 3-6 months. These observations
suggest that imatinib may affect skeletal tissue in vivo.
In human MSCs, imatinib blocks the MAPK/ERK and PI3K/Akt pathways by inhibiting
PDGFRb(185). Furthermore, it inhibits human MSC to proliferate and to differentiate into the osteogenic
lineage, favoring adipogenesis. The effect is mainly mediated though inhibition of PDGFRb with
pronounced effect on PI3K/Akt. In mouse osteoblastic lineage cell lines(66), imatinib promoted osteoblast
differentiation at the expense of cell proliferation. The authors suggested that the dominant effects in the
initial stage of imatinib therapy might be to increase bone formation, while continous treatment can lead
to depletion of osteoblasts because of anti-proliferative effects.
In the present study, we observed the similar results in periosteum derived cells in vitro. While
PDGF-BB promoted the proliferation and inhibited osteogenisis of PDCs, PDGFRb inhibitor abolished
the downstream signaling and rescued the inhibitory effects on ostegenic differentiation. There is no
animal study or human data so far regarding the effects of PDGFRb inhibitor on fracture healing. Since it
affect bone formation, at least in short term, this could open a direction for future studies.

MAPK and osteogenesis
The role of RTK or MAPK in osteogenic differentiation has been a controversial topic(110).
Conflicting observations exist in different cell lines, culture conditions, treatment of duration and
measurement of osteogenic differentiation. It is generally believed that mesenchymal stem cells remain
self-renewal by inducing proliferation and preventing differentiation(53). As MAPK is essential for cell
proliferation, it is inhibitory to cells progressing towards osteogenic pathway(113,186). MAPK has also been
proposed to be an agonist for osteogenic differentiation, mostly based on the inhibitor studies. MEK
inhibitors U0126 and PD98059 decreased OCN and BSP mRNA expression in MC3T3-E1 cells, although
these mature osteoblasts genes were examined at early time-points(187,188). Another in vitro study showed
that MAPK signaling phosphorylates and actives Runx2, thus stimulating osteogenesis(189).
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In the current study, we observed that PDGF-BB which acts via RTK antagonized osteogenic
differentiation of primary periosteal cells. The ERK/MAPK inhibitor U0126 can rescue the inhibitory
effect of PDGF on BMP2-Smad signaling. We also tried to examine the ERK inhibitor on periosteal
differentiation and found that primary cells were unhealthy during treatment while some could not survive
over 21 days (data not shown). Thus given the critical role MAPK to cell survival, even if MAPK
signaling is mildly antagonistic to osteogenesis, an increase in proliferation may affect bone regeneration
overall.

Other growth factors and bone formation
It has been discovered that over half of the genes expressed in the mouse genome were
differentially regulated over the course of fracture healing(190). The largest percentage of change were
associated with developmental process, metabolism elements, and components of cell signaling (both
intracellular and extracellular)(190). Besides PDGF, many other growth factors regulate the proliferation
and differentiation of osteoblastic lineage cells during bone regeneration(42).
FGF-2 is a member of the FGF family whose activity has been well examined in bone(191). It is
also a potent mitogen for mesenchymal cells, however its effect on osteogenic differentiation and bone
formation is complicated. While short-term FGF-2 treatment enhanced ALP colony formation of primary
BMSCs in vitro(192), continuous treatment with FGF-2 inhibited osteogenic differentiation(193,194). Multiple
lines of evidence also suggest the effects of FGF-2 to be stage specific(193,194). It can expand mesenchymal
progenitor population which result in enhanced bone formation, while the presence of FGF-2 during
osteogenic differentiation is inhibitory. Study on Fgf2-/- mice shows that FGF-2 stimulates osteoblast
differentiation and bone formation in vivo by the modulation of the Wnt pathway(195). FGF-2 primed
PDCs seem to have enhanced osteogenic differentiation potential, although the effects of continuous
FGF-2 treatment as well as intracellular signaling in PDCs is unknown(196).
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EGF is another similar growth factor which binds to receptor tyrosine kinase EGFR. It also
greatly inhibits osteoblast differentiation and blocks BMP2-induced osteogenesis in C2C12 cells,
presumably though Smurf1(197). Thus as previously discussed, whether the effect we observed is specific
to PDGF-BB or will also be seen with other growth factors in PDCs still remains an open question.
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4.4 Future directions
While the current study primarily focused on the effects of growth factors and signaling
interactions inside cells in vitro, future investigations should be more directed into understanding the
mechanism in vitro and further applications in vivo.

4.4.1 Mechanisms underlying the signaling interaction
Although the inhibitory effect of PDGF-BB on BMP2-Smad signaling in PDCs is detected in the
present study, molecular mechanism underlying this signaling interaction is still unknown. EGF has been
reported to modulate BMP2-Smad signaling through phosphorylating Smad1 linker site, leading to the
degradation of Smad1 protein(112). While it was previously examined in cell lines, similar effect of PDGFBB might also occur in primary PDCs which could be detected via immunoprecipitation. It would also be
interesting to examine whether this effect involves Smurf1, as Smurf1-dependent inhibitory
phosphorylation has been reported by EGF(197).

4.4.2 Other transgenic mouse model
In this thesis, we examined the effects of deleting PDGFRb in osteoprogenitor cell lineage during
early stage of fracture. While aSMACre is a nice model to target progenitor cells, an alternative choice is
Prx1CreER mice(198). Prx1CreER model has been shown to label osteochondro progenitor population in
the periosteum. As a transcription factor that plays an important role during skeletal development(199),
Prx1-driven Cre might be able to target a broader progenitor population.
Besides early response, the role of PDGF-BB in different lineage cells at other stages during
fracture is still unknown. This can be addressed by generating transgenic mouse models in which PDGFR
is targeted by distinct cell markers, and conditionally deleted at different time points by inducible Cre. We
have observed PDGFRb expression on Col2.3GFP expressing osteoblasts in fracture callus (data not
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shown), thus it would be interesting to learn how the loss of PDGFR signaling in osteoblasts would affect
fracture in vivo.

4.4.3 PDGFR inhibitor in vivo
Apart from genetically deleting PDGFRb in transgenic mice, another way to modulate PDGFRb
signaling is to use a PDGFR inhibitor in vivo. Since we observed that PDGFR inhibitor rescued PDGFBB inhibited osteogensis and BMP2 signaling in PDCs, treatment of PDGFR inhibitor combined with
BMP2 could potentially reduce BMP2 doses in vivo. Although the systemic treatment may not be able to
target specific cell type, it is still a promising strategy considering the transient increased bone formation
by imatinib observed in CML patients. The time of treatment can also be determined if specific phase of
fracture is meant to be targeted.
In addition, a more reproducible critical-sized femur defect model may be superior to the current
fracture model as discussed in Chapter 3. Under a standardized procedure, there seems to be lower
variability between mice. It also mimics the clinical bone non-union situation, in which BMP2 is widely
used. Comparing the effect of “standard” BMP2 treatment with BMP2+ PDGFR inhibitor will be more
informative to the signaling interaction in vivo. Reduced BMP2 doses with the addition of PDGFR
inhibitor may also be achieved given the in vitro data we obtained.

4.4.4 PDGF-BB, BMP2 and tissue engineering
An unexplored area of this thesis is to apply the current findings into tissue engineering. While
the concurrent treatment of PDGF-BB and BMP2 blocked osteogenic differentiation of PDCs in vitro, the
sequential combination enhanced osteogenesis comparing with control. Although no superior effect was
observed comparing with BMP2 treatment alone, this strategy reduced the total amount of BMP2 that
cells have been exposed. The proliferative progenitor cells stimulated by PDGF-BB could be further
induced into differentiation by BMP2.
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Recently, a novel drug delivery strategy has been developed by a special layer-by-layer coating
system(200), which makes sequential delivery of multiple factors possible. The coating is composed of a
biomimetic calcium phosphate (bCaP) layer which is applied to a synthetic bone graft and then covered
with a poly-L-Lysine/poly-L-Gultamic acid polyelectrolyte multilayer (PEM) film. In the primary study,
BMP2 was applied on the bone graft and bCaP-PEM was then deposited followed by absorption of FGF2 into PEM layer. The addition of bCaP layer to PEM prevents premature release of BMP2. When coated
scaffolds with BMP2 and FGF-2 were transplanted into mouse calvarial defects, improved bone defect
healing was observed. This strategy can also be applied to PDGF-BB and BMP2 in periosteum mediated
bone regeneration. Given the mitogenic effect of PDGF-BB and osteogenic effect of BMP2 in PDCs, we
could also expect a synergistic effect in vivo.

4.5 Conclusions
In conclusion, this thesis investigated the role of PDGF-BB/PDGFR-b in the context of
periosteum-mediated osteogenesis. We explored various response of PDCs to PDGF-BB in vitro and
discovered that PDGF-BB negatively modulate BMP2 signaling during osteogenic differentiation. In the
attempt to further understand its role in periosteum-mediated fracture healing in vivo, we generated a
conditional knockout mouse model to delete PDGFRb in aSMACre expressing cells. Our data suggests
that PDGFRb signaling plays a role in cell proliferation and differentiation during fracture healing.
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